Report on the risk assessment of 4-methylamphetamine in the framework of the Council Decision on new psychoactive substances. by unknown
IS
S
N
 1
7
2
5
-4
4
9
3
Report on the risk assessment  
of 4-methylamphetamine in the framework  
of the Council Decision on new  
psychoactive substances
About this series
EMCDDA Risk Assessments are publications 
examining the health and social risks of 
individual new psychoactive substances.
The Risk Assessment Report consists of an 
analysis of the scientific and law enforcement 
information available on the new psychoactive 
substance under scrutiny and the implications 
of placing it under control. It is the outcome of 
a meeting convened under the auspices of the 
EMCDDA Scientific Committee.
This process is part of a three-step procedure 
involving information exchange/early warning, 
risk assessment and decision-making in the 
framework of the Council Decision  
2005/387/JHA.
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I Foreword
It is with great pleasure that I present this comprehensive publication, which contains the 
data and findings of the risk assessment on the new psychoactive substance, 
4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA.
Concerns over the availability and use of this stimulant drug in the European Union led to 
an assessment of the health and social risks posed by the substance, and, consequently, 
its control across the EU Member States. The decision of the Council of the European 
Union to control 4-methylamphetamine, on the initiative of the European Commission, 
marks the final stage in the three-step process set up by Council Decision 2005/387/JHA 
on the information exchange, risk assessment and control of new psychoactive 
substances that allows the European Union to respond to potentially threatening new 
psychoactive substances.
Over the past few years much focus, rightly, has been given to the ‘legal highs’ 
phenomenon. Here, new psychoactive substances that mimic the effects of controlled 
drugs have been sold, often in attractive packaging, through head shops and the internet. 
The continued growth of this market has seen the issue of new psychoactive substances 
develop into an increasingly complex policy challenge that is now of major international 
concern. The chemical industries in China and India have been the focus of much 
discussion over the source of the bulk chemicals used in these products. Yet, the case of 
4-methylamphetamine serves as a stark reminder to us that new drugs continue to be 
produced in Europe (albeit likely that the precursors are sourced from third countries) and 
sold directly on the existing illicit drug market, rather than the all too familiar open market 
for ‘legal highs’ that is subject to almost daily media reports.
Crucial to understanding the reasons for taking action on 4-methylamphetamine are, first 
and foremost, the reports of acute toxicity that included 21 associated deaths, but also the 
large-scale production and trafficking of the drug in Europe. In this respect 4-methyl-
amphetamine also serves as a reminder of why a multi-disciplinary approach to the new 
drug phenomenon is essential, in this case with both law enforcement and health agencies 
playing a central role in helping to solve the riddle of where this drug came from, who was 
making it, who was distributing it, and the harms it posed to users. As it turned out, it was 
the same organised crime groups involved in the production of amphetamine that were 
responsible for the emergence of 4-methylamphetamine and its subsequent sale as 
amphetamine, ultimately placing at risk the amphetamine using population.
I would like to acknowledge the contribution and thank the members of the extended 
Scientific Committee of the EMCDDA, the EU Member States experts, the European 
Commission, Europol, the European Medicines Agency and the EMCDDA staff who 
participated in the risk assessment meeting, which took place on 16 November 2012 at 
the EMCDDA in Lisbon. The resulting report is a valuable contribution at European level, 
which gives clear support to political decision-making. Of course none of this would have 
been possible without the excellent work undertaken by the networks of the EMCDDA, 
Europol and the European Medicines Agency — the Reitox national focal points, Europol 
National Units, and the national competent authorities responsible for medicinal 
products — who, as ever, played an essential role in collecting and providing national data, 
thus ensuring a truly multidisciplinary effort.
Wolfgang Götz
Director, EMCDDA
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I Introduction
The appearance of 4-methylamphetamine on the amphetamine market in 2009 was 
something of a mystery. One inevitable question posed by those working in the new drugs 
field was whether, like many of the designer drugs that had appeared on the European 
market over the past two decades, 4-methylamphetamine was produced by accident or 
design. Was it deliberately manufactured because it was not covered by national or 
international law, or was it an attempt to circumvent legislation on precursor control?
The reason why 4-methylamphetamine emerged is still unclear, although tellingly, unlike 
the precursor used to manufacture amphetamine, the precursor for 4-methyl-
amphetamine, 4-methyl-BMK, is not under international control and appears to be 
commercially available. This did not change the fact that a new drug had emerged onto the 
European market for which there was limited information on its effects, including potential 
for harm. Compounding this was the fact that 4-methylamphetamine did not have to catch 
on first with users: its diffusion was assured as, unknown to both dealers and users, it was 
being sold as amphetamine on one of the largest established stimulant drug markets in 
Europe. This was a concern, given the fact that 21 deaths were associated with the 
substance at the time the risk assessment meeting was conducted.
To add to these concerns, it was soon found that the same organised crime groups that 
were involved in amphetamine were also responsible for the production, trafficking and 
distribution of the 4-methylamphetamine. By November 2012 the drug had been detected 
in 15 Member States, with production reported in one Member State.
4-Methylamphetamine belongs to the phenethylamine family and is chemically very close 
to amphetamine. Nonetheless, the literature review highlighted key differences in the 
pharmacology of the two substances. This included different effects on the 
monoaminergic system particularly in respect to 4-methylamphetamine’s actions on 
serotonin. In addition, concerns were raised over the possibility of caffeine to potentiate 
the toxicity of 4-methylamphetamine, which, given that the two substances were generally 
found in combination—and often together with amphetamine—requires further 
examination.
The absence of information and research findings has been a challenge for all risk 
assessments conducted by the Scientific Committee. Therefore, the risk assessment 
conclusions are inevitably based on partial knowledge and, consequently, are tentative. 
Many of the questions posed by the lack of evidence on the health and social effect of 
4-methylamphetamine could be answered by further research. Areas where additional 
information would be useful include studies on: metabolic pathways; clinical patterns of 
acute and chronic toxicity in humans; potential interactions with other substances 
(in particular caffeine and amphetamine); the dependence and abuse potential; and the 
social risks associated with its use. Both intended and unintended consequences of a 
decision to control 4-methylamphetamine should also be considered, as outlined in the 
present report.
Despite the challenges, the risk assessment exercise under Council Decision 2005/387/
JHA remains a unique element of the European action on new drugs and constitutes an 
important instrument to support decision-making at the level of the European Union. It can 
also be viewed as a useful mechanism to provide added value and support to national 
efforts in this area, and may serve as a good example of an evidence-based approach to 
sensitive policy issues.
RISK ASSESSMENTS I 4-Methylamphetamine (4-MA)
5 / 59
Introduction
Finally, I would like to thank all our colleagues from the extended Scientific Committee for 
sharing their knowledge and insights, which contributed to a stimulating and productive 
discussion. Also, I would like to express my appreciation to the external experts and to the 
EMCDDA staff who worked hard before, during and after the meeting to prepare and 
finalise the reports. I hope that these combined efforts will be appreciated by those to 
whom this report is addressed.
Professor Dr Gerhard Bühringer
Vice-Chair of the Scientific Committee of the EMCDDA
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I EMCDDA actions on monitoring and responding to new drugs
The EMCDDA has been assigned a key role in the detection and assessment of new drugs 
in the European Union under the terms of a Council Decision 2005/387/JHA on the 
information exchange, risk-assessment and control of new psychoactive substances. 
It establishes a mechanism for the rapid exchange of information on new psychoactive 
substances and provides for an assessment of the risks associated with them in order to 
permit the measures applicable in the Member States for the control of narcotic and 
psychotropic substances to be applied also to new psychoactive substances.
The three-step process involves information exchange/early warning, risk assessment and 
decision-making (see below). More detailed information can be found in the section ‘Action 
on new drugs’ of the EMCDDA’s website:  
www.emcdda.europa.eu/activities/action-on-new-drugs
Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, 
risk-assessment and control of new psychoactive substances
I. Information exchange
Early-warning system (EWS) EMCDDA–Europol Joint Reports
III. Decision-making Council Decisions on control
II. Risk assessment EMCDDA Risk Assessments
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I  EMCDDA–Europol Joint Report on 4-methylamphetamine: a summary
EMCDDA–Europol Joint Report on a new psychoactive substance: 
4-methylamphetamine — in accordance with Article 5 of Council Decision 
2005/387/JHA on the information exchange, risk assessment and control of new 
psychoactive substances
At the end of 2011 and in 2012, the EMCDDA and Europol examined the available 
information on a new psychoactive substance, 4-methylamphetamine, through a joint 
assessment based upon the following criteria: (1) the amount of the material seized; (2) 
evidence of organised crime involvement; (3) evidence of international trafficking; (4) 
analogy with better-studied compounds; (5) evidence of the potential for further (rapid) 
spread; and (6) evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information available on 4-methylamphetamine 
satisfies the above criteria. The two organisations therefore concluded that sufficient 
information has been accumulated to merit the production of a Joint Report on 
4-methylamphetamine as stipulated by Article 5.1 of the Decision. Accordingly, the Reitox 
NFPs, the European National Units (ENUs), the EMA and WHO were formally asked to 
provide the relevant information within six weeks from the date of the request, i.e. by 2 
July 2012.
The resulting Joint Report on 4-methylamphetamine was submitted to the Council, the 
Commission and the European Medicines Agency (EMA) on 30 July 2012. The report 
concluded that the health and social risks, caused by the use of, the manufacture of, and 
traffic in 4-methylamphetamine, as well as the involvement of organised crime and 
possible consequences of control measures, could be thoroughly assessed through a risk 
assessment procedure as foreseen by Article 6 of Council Decision 2005/387/JHA.
The full text of the Joint Report can be found at:
www.emcdda.europa.eu/publications/joint-reports/4-methylamphetamine
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measures can be applied in the Member States for narcotic 
and psychotropic substances (4).
There is emerging evidence that the new psychoactive 
substance 4-methylamphetamine has appeared on the drug 
market in Europe. In response to this, in compliance with the 
provisions of Article 5 of the Decision, on 31 July 2012, the 
EMCDDA and Europol submitted to the Council, the 
Commission and the European Medicines Agency (EMA) a 
Joint Report on the new psychoactive substance 
4-methylamphetamine (5). Taking into account the conclusion 
of the Joint Report and in accordance with Article 6 of the 
Decision, on 24 September 2012 the Council formally 
requested that ‘the risk assessment should be carried out by 
the extended Scientific Committee of the EMCDDA and be 
submitted to the Commission and the Council within twelve 
weeks from the date of this notification’.
In accordance with Article 6.2, the meeting to assess the risks 
of 4-methylamphetamine was convened under the auspices of 
the EMCDDA’s Scientific Committee with the participation of 
three additional experts designated by the Director of the 
EMCDDA, acting on the advice of the Chairperson of the 
Scientific Committee, chosen from a panel proposed by 
Member States and approved by the Management Board of the 
EMCDDA. The additional experts are from scientific fields that 
are either not represented, or not sufficiently represented, on 
the Scientific Committee, and whose contribution is necessary 
for a balanced and adequate assessment of the possible risks 
of 4-methylamphetamine, including health and social risks. 
Furthermore, two experts from the Commission, one expert 
from Europol and one expert from the EMA participated in the 
risk assessment. The meeting took place on 16 November 2012 
at the EMCDDA in Lisbon. The risk assessment was carried out 
on the basis of information provided to the Scientific 
Committee by the Member States, the EMCDDA, Europol and 
the EMA. A full list of the extended Scientific Committee and 
the list of participants attending the risk assessment meeting 
are included at the end of this publication.
(4)  In compliance with the provisions of the 1961 United Nations Single 
Convention on Narcotic Drugs and the 1971 United Nations Convention on 
Psychotropic Substances.
(5) www.emcdda.europa.eu/publications/joint-reports/4-methylamphetamine
I Introduction
This Risk Assessment Report presents the summary findings 
and the conclusions of the risk assessment carried out by the 
EMCDDA’s extended Scientific Committee of the new 
psychoactive substance 4-methylamphetamine. The report 
has been prepared and drafted in accordance with the 
conceptual framework and the procedure set out in the 
Operating guidelines for risk assessment of new psychoactive 
substances (EMCDDA, 2010) (1). It is written as a stand-alone 
document that presents a summary of the information 
considered during the detailed analysis of the scientific and 
law enforcement data available at this time. The conclusion of 
the report summarises the main issues addressed and 
reflects the opinions held by the members of the Committee. 
A more detailed ‘Technical report on 4-methylamphetamine’ is 
annexed to this report (Annex 1).
The risk assessment has been undertaken in compliance with 
Article 6 of Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange, risk assessment and control of 
new psychoactive substances (2) (hereinafter the ‘Decision’). 
The Decision establishes a mechanism for the rapid exchange 
of information on new psychoactive substances that may pose 
public health and social threats, including the involvement of 
organised crime, thus allowing European Union institutions 
and Member States to act on all new narcotic and 
psychotropic substances (3) that appear on the European 
Union drug scene. The Decision also provides for an 
assessment of the risks associated with these new 
psychoactive substances so that, if applicable, control 
(1)  EMCDDA (2010), Risk assessment of new psychoactive substances 
— operating guidelines, Publications Office of the European Union, 
Luxembourg. Available at: http://www.emcdda.europa.eu/html.cfm/
index100978EN.html
(2) OJ L 127, 20.5.2005, p. 32.
(3)  According to the definition provided by the Council Decision, a ‘new 
psychoactive substance’ means a new narcotic drug or a new psychotropic 
drug in pure form or in a preparation; ‘new narcotic drug’ means a substance 
in pure form or in a preparation that has not been scheduled under the 1961 
United Nations Single Convention on Narcotic Drugs, and that may pose a 
threat to public health comparable to the substances listed in Schedule I, II or 
IV; ‘new psychotropic drug’ means a substance in pure form or in a 
preparation that has not been scheduled under the 1971 United Nations 
Convention on Psychotropic Substances, and that may pose a threat to public 
health comparable to the substances listed in Schedule I, II, III or IV.
Risk Assessment Report  
of a new psychoactive substance:  
4-methylamphetamine
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The molecular structure, empirical formula, and molecular 
weight of 4-methylamphetamine are shown below (asterisk 
indicates chiral centre). The structure of amphetamine is also 
shown for reference.
The free base of 4-methylamphetamine is a nearly colourless 
liquid with an amine-like odour. The hydrochloride and sulfate 
salts are white or lightly coloured crystals. It is the salt form 
that is predominantly detected in seizures and collected 
samples (8, 9).
 4-Methylamphetamine has predominately been seized in 
powder and paste form, but liquids containing the substance 
have occasionally been encountered. A large proportion of the 
seized powders and pastes also typically contain 
amphetamine and caffeine in widely varying ratios. Solutions 
of the drug have also been seized, some of which contained 
amphetamine and/or caffeine (10). Tablets have been 
encountered infrequently. Additionally, other active 
substances including 4-methylethcathinone (4-MEC), 
methylenedioxymethylamphetamine (MDMA) and ketamine 
have been found in a small number of seizures and collected 
samples. There has been one report of 4-methylamphetamine 
detected in a commercial product called ‘Green Stinger’. A 
product bearing this name is sold on the internet as an 
‘ephedrine weight-loss product’ (4-methylamphetamine was 
not listed as an ingredient on this product).
(8)  ‘Detections’ is an all-encompassing term, which may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or specimens (tissues, hair, etc.).
(9)  For the sake of brevity, the term ‘4-methylamphetamine’ is used throughout 
the text although it is the hydrochoride or sulfate salt that is seen in seizures 
and collected samples. For methodological reasons, and because 4-methyl-
amphetamine is frequently mixed with other salt-forming stimulants, the 
inorganic acid is usually not specified by forensic laboratories that analyse 
samples.
(10)  Germany reported a seizure of a nasal spray that contained a colourless, 
clear liquid containing amphetamine, 4-methylamphetamine and caffeine. 
As hydrochlorides, the amphetamines are readily water-soluble and it is 
possible that the spray was home-made from a powder or paste.
For the risk assessment, the Scientific Committee considered 
the following:
(i)  Technical report on 4-methylamphetamine (November 
2012);
(ii)  Computational analysis on the pharmacology of 
4-methylamphetamine (September 2012) — EMCDDA-
commissioned study by Cambridge University;
(iii)  EMCDDA–Europol Joint Report on a new psychoactive 
substance 4-methylamphetamine (6);
(iv)  Scientific articles, official reports, grey literature and 
Internet drug user discussion forums;
(v)  Operating guidelines for risk assessment of new 
psychoactive substances (EMCDDA, 2010) (7);
(vi)  Council Decision 2005/387/JHA of 10 May 2005 on the 
information exchange, risk assessment and control of new 
psychoactive substances.
I  Physical and chemical description  of 4-methylamphetamine and  its mechanisms of action, including  its medical value
4-Methylamphetamine is a synthetic phenethylamine 
stimulant. It is a ring-methylated derivative of amphetamine. It 
has many synonyms (listed in Annex 1) but the systematic 
(International Union of Pure and Applied Chemistry, IUPAC) 
name of 4-methylamphetamine is 1-(4-methylphenyl)propan-
2-amine. It is also important to distinguish 4-methyl-
amphetamine from the substance commonly known as 
methamphetamine (‘meth’) that is correctly called 
N-methylamphetamine.
(6)  http://www.emcdda.europa.eu/publications/joint-reports/4-
methylamphetamine
(7) http://www.emcdda.europa.eu/html.cfm/index100978EN.html
H3C
*
CH3
NH2
*
CH3
NH2
4-Methylamphetamine Amphetamine
Empirical formula: C
10
H
15
N
Molecular weights: 149.23 (base); 185.69 (HCl salt); 396.54 ((C
10
H
15
N)
2
·H
2
SO
4
 salt, i.e. Aptrol, see below).
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used for any other legitimate purpose. There are no known 
uses of 4-methylamphetamine as a component in industrial, 
cosmetic or agricultural products.
Data on the pharmacokinetics of 4-methylamphetamine are 
limited to one study reported in 1950 of six volunteers 
suggesting anorectic effects lasting 6–10 hours and 
significant hypertension lasting 20–30 minutes, both of 
which were dose dependent. In addition, one user reported 
‘psychedelic effects’ with a ‘plateau at two hours, and 
baseline at four hours’. There is no published information on 
the biotransformation (metabolism) of 4-methylamphetamine 
in animals or humans. It is reasonable to assume, however, 
that metabolism follows the biochemical pathways 
established for structurally related substances (such as 
mephedrone).
There have been a number of studies in animals that have 
investigated the pharmacodynamics of 4-methyl-
amphetamine. Typically these have compared it to 
amphetamine and/or other ring-substituted amphetamines. 
These studies suggest that 4-methylamphetamine has effects 
on stimulating the release and inhibiting the reuptake of 
serotonin, dopamine and noradrenaline in the brain. Overall, in 
comparison to amphetamine, it appears to have greater 
effects on serotonin reuptake than dopamine or noradrenaline. 
Furthermore, 4-methylamphetamine has been found to be 
more potent than amphetamine in inhibiting animal brain 
monoamine oxidase (MAO) leading to elevated dopamine, 
and, in particular, serotonin levels both in vitro and in vivo.
One animal study demonstrated that pre-treatment with 
caffeine potentiated the anorectic effects of 4-methyl-
amphetamine. This effect was not seen with amphetamine. 
However, no studies have investigated the co-administration 
of 4-methylamphetamine with amphetamine and/or caffeine, 
therefore there are no data on the possible drug interactions. 
This is important, given the fact that the most prevalent 
situation observed in the illicit market involves all three 
substances together.
Animal models suggest that although 4-methylamphetamine 
has a similar median lethal dose (LD
50
) to amphetamine, there 
is variation based on the model used and the route of 
administration. One study in an animal model also suggests 
that the pharmacological spectrum of 4-methylamphetamine 
is more LSD-like than that of amphetamine, though much less 
active than 2,5-dimethoxy-4-methylamphetamine (DOM).
4-Methylamphetamine was the least likely to cause self-
administration in an animal study that compared the self-
administration of 4-methylamphetamine with amphetamine, 
3-methylamphetamine, 3-fluoroamphetamine and 
4-fluoroamphetamine.
Analysis using gas chromatography (GC) and liquid 
chromatography (LC) coupled with mass spectrometry (MS) 
is straightforward. Though the 2-, 3- and 4- positional isomers 
have virtually identical mass spectra, they can be 
distinguished based on their retention time. It should be 
noted that 4-methylamphetamine (and its positional isomers) 
have the same empirical formula as N-methylamphetamine. 
This may present an analytical issue if using accurate mass 
spectrometry without subsequent fragmentation. The infrared 
and nuclear magnetic resonance spectra of the positional 
isomers are different. Analytical reports of 4-methyl-
amphetamine of seized, collected and biological samples 
have not indicated the presence of the 2- or 3- positional 
isomers nor are data available on the enantiomeric 
composition of 4-methylamphetamine found in these 
samples (11).
In the 1950s, 4-methylamphetamine was studied by Smith, 
Kline & French Laboratories as a potential anorectic medicine 
under the trade name Aptrol (12). However, its development 
and marketing was abandoned for unknown reasons and it 
was never made commercially available. Claims have been 
made in the scientific and patent literature on the use of 
4-methylamphetamine as a potential medicine and as an 
intermediate in the synthesis of potential medicines. It should 
be noted, however, that patents may contain broad claims and 
the inclusion of a chemical structure in a patent does not 
mean that the substance will be developed and/or 
commercialised as a medicinal product.
4-Methylamphetamine has no established or acknowledged 
medical value or use (human or veterinary) in the European 
Union. There is no marketing authorisation (existing, ongoing or 
suspended) for 4-methylamphetamine in the European Union 
or in the Member States that responded to the EMA’s 
information request launched under Article 5 of the Decision. 
There is no information that 4-methylamphetamine is used for 
the manufacture of a medicinal product or an active 
pharmaceutical ingredient (API) of a medicinal product in the 
European Union. However, it should be noted that there is no 
European Union database on the synthetic routes of all 
registered medicinal products. The use of 4-methyl-
amphetamine cannot be ruled out with certainty.
4-Methylamphetamine is used as an analytical reference 
standard and in scientific research (in the latter case, often in 
combination with amphetamine and related compounds, 
some of which are under international control). There are no 
other indications that 4-methylamphetamine is currently being 
(11)  Published biological studies, including toxicological ones, have used the 
racemic mixture. It is not known whether there are substantial differences 
between the pharmacology of 4-methylamphetamine enantiomers.
(12)  The trade name Aptrol originally referred to the sulfate salt comprised of two 
moles of 4-methylamphetamine and one mole of sulfuric acid.
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I  Health risks associated with 4-methylamphetamine
I Individual health risks
The assessment of individual health risks includes a 
consideration of the acute and chronic toxicity of 4-methyl-
amphetamine, as well as its dependence potential, and its 
similarities to and differences from other chemically related 
stimulants.
There are limited data available on the main routes of 
administration for 4-methylamphetamine. However, a small 
number of user reports, together with extrapolation from the 
routes of administration for amphetamine, suggest that these 
may include oral ingestion (swallowing), nasal insufflation 
(snorting), intramuscular and intravenous injection, and rectal 
insertion. It is likely, given that 4-methylamphetamine is sold 
and used as amphetamine, that the most common routes of 
use reflect those used for amphetamine.
Systematic data are not routinely collected in Europe on acute 
toxicity related to 4-methylamphetamine. There are no recent 
studies. There has only been one case study published on an 
individual using 4-methylamphetamine, 4-methylmeth-
amphetamine and alcohol. There are also limited data from a 
volunteer study and a clinical trial investigating 
4-methylamphetamine. The effects described are similar to 
those seen with other stimulant drugs such as amphetamine.
Adverse effects reported by users include headache, heavy 
sweating, nausea, abdominal pains, high blood pressure, 
flutter, headache, paranoia, hallucinations, anxiety and 
depression, empathy and euphoria, with post-use effects such 
as insomnia, ‘cognitive disorder’ and ‘mood disorder’. These 
are based on self-reports, and a limitation is that users may 
not have used 4-methylamphetamine. In addition, they may 
have used other substances which may account for some or 
all the described effects.
The adverse effects reported in the volunteer study of 
4-methylamphetamine administration were dose-related 
hypertension and anorectic effects, nausea, sweating, gastric 
distress, hypersalivation, expectoration and coughing. The 
adverse effects reported in the clinical trial of 4-methyl-
amphetamine as an anorectic agent were headache, pruritis 
and palpitations. There was no significant difference between 
4-methylamphetamine and placebo in terms of effects on 
blood pressure and heart rate. However, the limitations in the 
design of these studies restrict the interpretation of these 
adverse effects.
There are no published studies that have formally assessed 
the psychological and/or behavioural effects of 
4-methylamphetamine in humans.
A human volunteer study and a clinical trial conducted in the 
1950s have shown that 4-methylamphetamine is associated 
with hypertension, anorexia, nausea, perspiration, gastric 
distress, coughing, vomiting, headache, pruritis and 
palpitations. Additionally, unconfirmed user reports, some of 
which involved multiple co-used substances, suggest similar 
adverse effects as well as insomnia, paranoia, anxiety, 
depression and ‘nervousness and stimulation resembling 
ephedra’.
I  Chemical precursors that are used for the manufacture of 4-methylamphetamine
The synthesis of 4-methylamphetamine requires similar 
equipment and chemical expertise to those needed for the 
manufacture of other amphetamines. Most of the published 
methods for the synthesis of 4-methylamphetamine rely on 
the reductive amination of the precursor 4-methylbenzyl 
methyl ketone (4-methyl-BMK) (13) and, in particular, use the 
Leuckart reaction. These reactions are feasible in an amateur 
laboratory setting and do not require sophisticated 
equipment. Although the methods used to produce 4-methyl-
amphetamine currently on the illicit drug market are not 
specifically known, the presence of detectable levels of 
4-methyl-BMK in some samples indicates this is one of the 
precursors used. Studies conducted on seized samples and 
investigations at illicit manufacturing sites suggest that the 
methods of synthesis noted above have been used.
The relevant precursor 4-methyl-BMK can be potentially used 
in general organic synthesis. It appears to be commercially 
available and is not under international control.
It has been hypothesised that the presence of 
4-methylamphetamine in amphetamine samples may be due 
to changes in the availability of precursors used for the illicit 
synthesis of amphetamine.
(13)  Other chemical names are 4-methylphenylacetone and 1-(4-methylphenyl)
propan-2-one. The CAS Registry Number for this ketone is 2096-86-8.
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As noted, in almost all cases 4-methylamphetamine is being 
sold as amphetamine and most users will be unaware that 
they are consuming the substance.
In general, the quality (purity) of 4-methylamphetamine 
appears to be variable but the situation is made more complex 
by the presence of amphetamine and/or caffeine in many 
samples. In many cases, seized samples have not been 
quantitatively analysed and so the relative proportions of 
active substances are not known. In cases where the amount 
of 4-methylamphetamine has been determined, it has varied 
from trace or low amounts with a small number of reports 
where 4-methylamphetamine is reported as the main or sole 
component of the mixture. Data from samples collected from 
users in the Netherlands from 2010 to mid-2012 found that 
between 7 and 13 % of ‘speed’ samples contained both 
4-methylamphetamine and amphetamine, with a smaller 
proportion (less than 2 %) containing 4-methylamphetamine 
only (the presence of caffeine was not reported). There has 
also been a small number of samples containing 
4-methylamphetamine where active substances other than 
amphetamine and caffeine have been detected.
There are limited data available on the prevalence of use of 
4-methylamphetamine. Non-representative studies of 
‘psychedelic users’ in Hungary and attendees at gay-friendly 
nightclubs in London, United Kingdom suggest self-reported 
lifetime use of 4-methylamphetamine of 2.1 and 5.8 % 
respectively. It is possible that in at least some cases, 
participants reporting the use of 4-methylamphetamine were 
actually referring to ‘methamphetamine’. Given that most 
exposures to 4-methylamphetamine occur when users 
attempt to use amphetamine, it is worth noting that drug 
prevalence estimates suggest that about 2 million Europeans 
have used amphetamines during the last year (14). 
Consequently, populations using amphetamines may be at 
risk of exposure to 4-methylamphetamine if this substance 
remains on the illicit drug market.
It is likely that 4-methylamphetamine will be used in similar 
environments as amphetamine. These include nightclubs/
discos, bars/pubs, outdoor music festivals and home 
environments. The route of supply of 4-methylamphetamine is 
through street-level drug dealers.
Aside from what is known from the limited studies noted 
above, there is no further information on the nature and extent 
of health consequences. In particular there are no European 
data on acute emergency department presentations related to 
4-methylamphetamine toxicity. One study has noted the 
(14)  Amphetamines is a generic term that includes both amphetamine and 
methamphetamine — and it is important to note that there have been no 
indications that 4-methylamphetamine has been sold as 
‘methamphetamine’.
Although there have been reports of detection of 
4-methylamphetamine in non-fatal intoxications, there are 
insufficient clinical details in these reports to be able to 
determine the clinical pattern of acute toxicity seen. Most 
exposures to 4-methylamphetamine appear to occur where 
individuals have used ‘speed’ (amphetamine), i.e. users are 
unaware that they have taken 4-methylamphetamine. 
Therefore, it may be the case that the acute toxicity related to 
the use of 4-methylamphetamine is underreported.
To date, there have been a total of 21 fatalities from four 
Member States (Belgium, Denmark, the Netherlands and the 
United Kingdom) where 4-methylamphetamine alone or in 
combination with one or more other substance has been 
detected in post-mortem samples, especially amphetamine. It 
is not possible to determine with certainty the role of 
4-methylamphetamine in these fatalities from the available 
information. However, in some cases 4-methylamphetamine 
was the predominant drug detected, with levels comparable to 
those found in some amphetamine deaths.
While there are insufficient clinical details in the non-fatal and 
fatal intoxications to be able to determine the clinical pattern 
of acute toxicity, evidence of hyperthermia has been 
reported.
No studies have been published investigating the potential for 
chronic 4-methylamphetamine toxicity in humans, including 
reproductive toxicity, genotoxicity and carcinogenic potential. 
However, there has been one limited animal study 
investigating the sub-acute and chronic toxicity suggesting 
that 4-methylamphetamine was not associated with 
histological changes in a number of organs.
In summary, from the limited data sources available, it 
appears that the acute toxicity of 4-methylamphetamine is 
similar to other stimulants. However, there is some evidence 
that in combination with other substances including 
amphetamine and caffeine, there may be a higher risk of 
overall enhanced toxicity. While there have been reports of 
fatalities where 4-methylamphetamine was detected, it is 
difficult to determine the role of the drug in these fatalities 
from the available information. However, 4-methyl-
amphetamine was recorded as the cause of death in certain 
cases.
I Public health risks
The public health risks associated with 4-methylamphetamine 
may be categorised in terms of the extent, frequency and 
patterns of use; availability and quality of the drug; information 
availability and levels of knowledge amongst users; and 
negative health consequences.
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Sweden has reported six cases where crimes were associated 
with 4-methylamphetamine as a factor; however, details of 
these cases are not available.
It is not possible at this time to estimate whether 
4-methylamphetamine is associated with higher healthcare 
costs than other stimulant drugs given the lack of data.
As noted, 4-methylamphetamine has been identified in the 
serum of a small number of vehicle drivers. The significance of 
this finding is unclear.
I 
 Information on the level of involvement of 
organised crime and information on 
seizures and/or detections by the 
authorities, and the manufacture of 
4-methylamphetamine
The available information suggests that 4-methylamphetamine 
is produced and trafficked by the same organised crime 
groups that are involved with the manufacture and trafficking 
of amphetamine. There is no specific information that criminal 
groups are knowingly and systematically involved in the 
manufacture, trafficking and/or distribution of 
4-methylamphetamine.
The only Member State to have reported the detection of illicit 
manufacture of 4-methylamphetamine is the Netherlands. In 
2010, 4-methylamphetamine was detected in four illicit 
amphetamine laboratories. In August 2011, traces of 
4-methylamphetamine were found at an amphetamine 
crystallisation site. In 2012, small amounts of 4-methyl-
amphetamine were detected in two cases related to the illicit 
production of the amphetamine precursor benzyl methyl ketone 
(BMK) from the non-controlled pre-precursor alpha-
phenylacetoacetonitrile (APAAN). In one of the cases, in which 
600 kg of APAAN was seized at a trailer park, the presence of 
4-methyl-BMK was also detected (in residues) at the site. 
Information from Dutch police suggests that some producers 
believed they were using BMK to produce amphetamine. 
However, it appears they were actually using 4-methyl-BMK and 
as a result were inadvertently producing 4-methylamphetamine.
There are a number of reports where 4-methylamphetamine 
has been trafficked from the Netherlands to Germany, France 
and the United Kingdom. These seizures amount to more than 
240 kg of powder/paste and 9 kg of liquid containing 
4-methylamphetamine. The largest of these seizures was 
147 kg of paste also containing amphetamine and caffeine. 
This was intercepted in France en route to the United 
detection of 4-methylamphetamine in five serum samples of 
vehicle drivers in Germany. However, additional information is 
not available to allow further assessment.
4-Methylamphetamine is not commercially marketed through 
Internet shops aimed at users (i.e. those selling ‘legal highs’ or 
‘research chemicals’). One Member State noted that 
4-methylamphetamine was being offered for sale in classified 
adverts on the Internet in October 2011. Some websites/web 
portals listed chemical suppliers that could purportedly offer 
4-methylamphetamine for sale. No countries reported 
seizures or collected samples linked to sale of the drug on the 
Internet. Norway reported a single seizure by customs 
authorities in 2009 where 4-methylamphetamine was 
detected in a ‘weight loss’ product and they noted that this 
product is offered for sale on the Internet. 4-Methyl-
amphetamine is, however, available from Internet sites as an 
analytical reference standard or for scientific research 
purposes.
I  Social risks associated with 4-methylamphetamine
There is a lack of data upon which to allow sufficient reasoned 
discussion on the social risks associated with 4-methyl-
amphetamine. However, given that it is sold as amphetamine it 
is possible to draw inferences from what is known about the 
amphetamine market.
The European amphetamine market can be characterised by 
two main patterns of use. The biggest group of users are 
generally episodic or occasional users of the drug, most of 
whom are relatively well-integrated socially. Here, patterns of 
use among this group will vary from occasional experimental 
use (only once or twice) to regular episodic but intensive 
periods of use. A second, more chronic, pattern of use can 
also be found in some countries, notably Norway, Latvia, 
Sweden and the United Kingdom. This pattern of use is 
characterised by long-term injection of amphetamine, which is 
often in high dose. These users tend to be more socially 
marginalised and suffer from more chronic health problems.
There have been no studies to determine the impact of 
4-methylamphetamine use on educational outcomes such as 
attendance, concentration and exam performance. Similarly, 
there are no data on the effect of 4-methylamphetamine use 
on performance/attendance at work, career progression, 
effects on personal relationships or neglect of family.
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Lithuania and the United Kingdom, 4-methylamphetamine is 
controlled using a generic definition of phenethylamines.
Belgium and Italy have noted that they intend to introduce 
such controls. 4-Methylamphetamine is not controlled in 
Norway or Turkey.
In addition, Austria and Hungary have legislation prohibiting 
the unauthorised supply of defined or qualifying psychoactive 
substances and control 4-methylamphetamine within a 
generic definition of phenethylamines.
Finland uses their medicines legislation to control 
4-methylamphetamine.
It should be noted that laws were passed in Ireland (in 2010), 
Poland (2010) and Romania (2011) that prohibit the 
unauthorised supply of any psychoactive substance that 
qualifies by conforming to certain criteria. National authorities 
may find that 4-methylamphetamine meets such criteria.
I  Options for control and the possible consequences of the control measures
Under Article 9.1 of the Decision, the option for control that is 
available at European Union level is for the Member States to 
submit the new psychoactive substance 4-methyl-
amphetamine to control measures and criminal penalties, as 
provided for under their legislation, by virtue of their 
obligations under the 1971 UN Convention on Psychotropic 
Substances. There are no specific European studies on the 
possible consequences of such control measures. If this 
option of control is pursued, the Committee considers that the 
following consequences are possible. Some of these may 
apply to any new psychoactive substance.
n  This control could facilitate the detection, seizure and 
monitoring of 4-methylamphetamine related to its illegal 
manufacture, trafficking and use. In so doing, it could 
facilitate international cooperation between the judicial 
authorities and law enforcement agencies. As 
4-methylamphetamine is already present in the illegal 
market being sold as amphetamine, it is unlikely that 
control measures would increase the size of the illicit 
amphetamine market with the increased risk of associated 
criminal activity, including organised crime.
n  A health consequence that may result from control 
measures is the benefit brought about by the presumed 
reduction in availability and use.
Kingdom. Furthermore, French authorities intercepted one 
seizure en route to Spain.
There is no information to suggest that distribution networks 
other than those established for amphetamine are being used. 
It does not appear, based on the information available to the 
ECMDDA and Europol, that the manufacture, trafficking, and 
distribution of 4-methylamphetamine impacts on other 
existing psychoactive substances or new psychoactive 
substances (apart from amphetamine).
In summary, some organised crime groups involved in the 
manufacture, trafficking, and distribution of amphetamine 
(and in some cases its main precursors) are also involved in 
the manufacture, trafficking and distribution of 
4-methylamphetamine.
I  Information on any assessment of 4-methylamphetamine in the United Nations system
The World Health Organization (WHO) is the specialised United 
Nations (UN) Agency designated for the evaluation of the 
medical, scientific and public health aspects of psychoactive 
substances under the 1961 UN Single Convention on Narcotic 
Drugs and the 1971 UN Convention on Psychotropic 
Substances. On 22 June 2012, WHO informed the EMCDDA 
that 4-methylamphetamine is currently not under assessment 
and has not been under assessment by the UN system.
I  Description of the control measures that are applicable to 4-methylamphetamine in the Member States
4-Methylamphetamine is not listed for control in the 1961 UN 
Single Convention on Narcotic Drugs and the 1971 UN 
Convention on Psychotropic Substances (together ‘UN drug 
conventions’).
Nineteen Member States do not control 4-methylamphetamine 
under legislation derived from their obligations under the UN 
drug conventions. The remaining eight Member States (Cyprus, 
Denmark, France, Germany, Ireland, Lithuania, the Netherlands 
and the United Kingdom) and Croatia control 
4-methylamphetamine under legislation derived from the 
obligations under the UN drug conventions. In Cyprus, Ireland, 
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The physical effects of 4-methylamphetamine have rarely 
been reported by users as they are typically unaware they 
have taken the substance. However, the few reports that are 
available suggest stimulant-type effects. There are no 
published formal studies assessing the psychological and/or 
behavioural effects of 4-methylamphetamine in humans. In 
animal studies, 4-methylamphetamine has been shown to 
affect the monoaminergic systems differently from 
amphetamine, in particular in respect to its action on 
serotonin. Limited available data in humans suggest that the 
adverse effects of 4-methylamphetamine include 
hyperthermia, hypertension, anorexia, nausea, perspiration, 
gastric distress, coughing, vomiting, headache, pruritis, 
palpitations, insomnia, paranoia, anxiety and depression.
4-Methylamphetamine is generally found in combination with 
amphetamine and/or caffeine. There are no data to be able to 
determine the clinical significance and risks associated with 
these combinations. However, there are concerns about the 
increased risks posed by using this substance in combination 
with other psychoactive substances, in particular with respect 
to amphetamine and caffeine.
Prevalence specific to 4-methylamphetamine is difficult to 
estimate. There is no specific demand for the substance. It is 
sold as amphetamine, with users unaware they are consuming 
it. Thus, it can be assumed that the amphetamines-using 
population — an estimated 2 million Europeans during the last 
year — may be at risk of exposure to the drug.
The available data from animal studies indicate that the risk of 
acute toxicity for 4-methylamphetamine when administered 
on its own is similar to that of amphetamine. 4-Methyl-
amphetamine has been detected in 20 non-fatal intoxications 
or drug-related offences. However, there is insufficient 
information in these cases to be able to characterise the 
pattern of toxicity in humans. The chronic health effects, 
including reproductive toxicity, genotoxicity and carcinogenic 
potential in humans are unknown.
4-Methylamphetamine has been detected in 21 fatalities in 
four Member States, either alone or in combination with one 
or more substances. The results of the statutory investigations 
(e.g. coroners’ findings) into most of the deaths are not 
available. However, it has been mentioned in the cause of 
death in some cases.
Current data are not sufficient to determine the relative 
dependence-producing potential of 4-methylamphetamine.
4-Methylamphetamine has been detected in 15 Member 
States and two other countries that report to the EMCDDA. It 
has the potential to diffuse to other countries and this may 
constitute a health and social threat. Diffusion appears to be a 
n  Control measures would not necessarily imply additional 
costs related to law enforcement, criminal justice, forensic 
analysis, testing, etc., as amphetamine is already controlled 
in the Member States.
n  It is not possible to predict whether there will be health or 
social consequences from any substance(s) that might be 
manufactured as a result of this control, such as other 
non-controlled substituted amphetamines.
n  At present, there is no reason to expect that this control 
would impact on current or future research by the 
pharmaceutical or chemical industries.
In order to examine the consequences of control, the 
Committee wishes to note that it will be important to monitor 
for the presence of 4-methylamphetamine on the market 
post-control, should this option be pursued.
Aside from the option for control under those stipulated in 
Article 9.1 of the Decision, other options for control may be 
available to Member States. As noted, some Member States 
have regulated 4-methylamphetamine under medicines 
legislation and some have imposed restrictions on the 
importation and supply of the substance.
Although outside the scope of the Decision, it may be 
important to monitor the availability of the precursors used for 
the manufacture of 4-methylamphetamine (e.g. 4-methyl-
BMK). Reducing the availability of precursors may limit the 
manufacture and availability of the drug.
I Conclusion
4-Methylamphetamine is a stimulant drug. It is a synthetic 
ring-methylated derivative of amphetamine. It is found mostly 
as a powder but also as a paste, in liquids and in tablets. It has 
no established or acknowledged medical use (human or 
veterinary) in the European Union. There are no indications 
that it may be used for any other purpose aside from as an 
analytical reference standard and in scientific research (this is 
often in combination with amphetamine and related 
compounds, some of which are under international control).
It has emerged on the illicit amphetamine market where it is 
sold and used as amphetamine. This appears to be due to 
changes in the supply of precursor materials used in the 
manufacture of amphetamines. It is often detected in 
mixtures along with amphetamine and/or caffeine. The main 
precursor for its synthesis, 4-methyl-BMK, is commercially 
available. There has been one report of where 4-methyl-
amphetamine was detected in a ‘dietary supplement’ sold as 
a ‘weight loss’ product.
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function of precursor availability rather than demand from 
users.
The social consequences associated with the use of any drug 
are likely to be influenced by a number of factors. However, 
data specific to 4-methylamphetamine are extremely limited, 
although there appears to be no specific user demand for the 
drug.
4-Methylamphetamine appears to be sold on the illicit 
amphetamine market by street-level drug dealers. Organised 
crime is involved in manufacture, trafficking and supply.
Many of the questions posed by the lack of evidence on the 
health and social risks of 4-methylamphetamine, as for any 
new psychoactive substance, could be answered through 
further research. Areas where additional information would be 
useful include: metabolic pathways for 4-methylamphetamine; 
acute and chronic clinical patterns of toxicity in humans; the 
potential interaction between 4-methylamphetamine and 
amphetamine and/or caffeine as well as other substances 
(including medicines that affect the serotonergic system, e.g. 
selective serotonin reuptake inhibitors); the dependence and 
abuse potential; and the social risks associated with its use.
The Committee notes that a decision to control this drug has 
the potential to bring with it both positive and negative 
consequences. Potential positive consequences include 
reduced levels of manufacture, availability and ultimately use. 
This may reduce the health and social risks and consequences 
of 4-methylamphetamine. It is important to recognise that a 
potential unintended consequence of control may be the 
manufacture and availability of other substances. Finally, 
control should not inhibit the gathering and dissemination of 
accurate information on 4-methylamphetamine to users, 
practitioners and decision-makers.
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limited information available that suggests that 4-methyl-
amphetamine is used orally, by nasal insufflation, and by 
intramuscular injection. The doses reported range from 
10–300 mg.
There is limited information available on the prevalence of use 
of 4-methylamphetamine as there are currently no co-
ordinated national or European population surveys on 
4-methylamphetamine use. Two small surveys (Hungary and 
the United Kingdom) have shown self-reported/suspected use 
of 4-methylamphetamine in a small minority (2.1–5.8 %) of 
those surveyed. It is possible that in at least some cases, 
participants reporting the use of 4-methylamphetamine were 
actually referring to ‘methamphetamine’ (N-methyl-
amphetamine). Since most exposures appear to occur where 
individuals have attempted to source/use amphetamine 
(‘speed’), there is the potential that use is in fact greater than 
reported. Additionally, it is likely that the routes of supply of 
4-methylamphetamine will be the same as those for 
amphetamine (e.g. through street level drug dealers).
The only reports of crime and antisocial behaviour related to 
4-methylamphetamine use are from Sweden; amphetamine 
was also involved in all of these cases. There have been 
reports of seizures of 4-methylamphetamine (together with 
amphetamine) crossing international borders in the European 
Union.
Data on the pharmacokinetics of 4-methylamphetamine are 
limited to one small clinical trial reported in 1950 of six 
volunteers in which anorectic effects lasted 6–10 hours and 
significant hypertension lasted 20–30 minutes. In addition, 
one user reported ‘psychedelic effects’ with a ‘plateau at two 
hours, and baseline at four hours’.
There have been a number of animal models that have 
investigated the pharmacodynamics of 4-methyl-
amphetamine; typically these have compared it to 
amphetamine and/or other ring substituted amphetamines. 
These studies suggest that 4-methylamphetamine has effects 
inhibiting re-uptake and stimulating the release of dopamine, 
serotonin and noradrenaline. Overall it appears to have greater 
I Summary
4-Methylamphetamine is a synthetic phenethylamine 
stimulant. It is a ring-methylated derivative of amphetamine. 
Although the drug underwent human clinical trials as an 
anorectic agent (trade name Aptrol) in the 1950s, it has no 
current known legitimate industrial, agrochemical, cosmetic, 
human or veterinary medical use.
4-Methylamphetamine has appeared sporadically on the illicit 
drug market. The first detection was reported in the United 
States of America in 1973; subsequently a report of its 
detection was published in the United Kingdom in 1989. Since 
the introduction of the European Union early-warning system 
in 1997, 4-methylamphetamine was first detected (1) in 
Belgium in a seizure made in October 2009, with formal 
notification to the EMCDDA in December 2009. There have 
been reports to the EMCDDA and Europol of seizures and 
collected samples of 4-methylamphetamine in 15 Member 
States and two other countries that report to the EMCDDA. 
Most commonly 4-methylamphetamine is found together with 
amphetamine and caffeine. In only a few cases has 
4-methylamphetamine been the only active substance in a 
seized sample. Generally the analyses have been qualitative 
and the relative proportion of active ingredients, including 
4-methylamphetamine, in the seized products was not 
estimated. In some of the seizures, the exact position of 
methyl group in the aromatic ring of the methylamphetamine 
has not been established and so it is not possible to be 
definitively certain that the substance contained 
4-methylamphetamine and not the 2- or 3-methyl isomer.
Most commonly 4-methylamphetamine is encountered in 
powder or paste form (commonly white, white-yellow, off-
white or yellow). 4-Methylamphetamine has also been 
detected in liquids and to a lesser degree tablets. There is 
(1)  ‘Detections’ is an all-encompassing term, which may include seizures and/or 
collected and/or biological samples. Seizure means a substance available 
(seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug 
monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, 
etc.) and/or specimens (tissues, hair, etc.).
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Annex 1
use of 4-methylamphetamine and associated toxicity and 
risks may be greater than is evident from the data that are 
currently available.
I  Section A. Physical, chemical, pharmaceutical and pharmacological information
I  A1. Physical, chemical and pharmaceutical information
A1.1. Physical and chemical description
Chemical description and names
4-Methylamphetamine is a synthetic phenethylamine 
stimulant. It is a ring-methylated derivative of amphetamine. In 
the 1950s it was studied by Smith, Kline & French 
Laboratories as a potential anorectic medicine under the trade 
name Aptrol (3).
The systematic (International Union of Pure and Applied 
Chemistry, IUPAC) name of 4-methylamphetamine is 
1-(4-methylphenyl)propan-2-amine. Other chemical names 
encountered in the literature include: 1-(4-methylphenyl)-2-
aminopropane; 2-amino-1-(4-methylphenyl)propane or 
2-amino-1-(p-methylphenyl)-propane; 1-(4-methylphenyl)-2-
propylamine; α,4-dimethylbenzeneethaneamine (Chemical 
Abstract name); 1-(4-methylphenyl)-1-methylethanamine; 
p,α-dimethylphenethylamine; 4-methyl-α-methyl-
phenethylamine; para-methylamphetamine or 
p-methylamphetamine; 1-methyl-2-p-tolyl-ethylamine; 
1-(p-tolyl)-2-aminopropane; 1-(p-tolyl)propan-2-amine; 
4-methylphenylisopropylamine; 1-methyl-2-p-tolyl-aethylamin; 
2-amino-1-p-tolyl-propan; and, β-p-toluylisopropylamine. The 
Chemical Abstract Service (CAS) Registry Numbers for 
4-methylamphetamine are given in Table 1.
(3)  The trade name Aptrol originally referred to the sulfate salt comprised of two 
moles of 4-methylamphetamine and one mole of sulfuric acid.
effects on brain serotonin levels. Importantly, none of these 
studies involved the co-administration of 
4-methylamphetamine with amphetamine and/or caffeine, 
which is the most prevalent situation observed in the illicit 
market. As a result there are no data on possible drug 
interactions.
Animal models suggest that although 4-methylamphetamine 
has a similar median lethal dose to amphetamine there is 
variation based on the model used and the route of 
administration. Human volunteer studies and user reports 
have shown that 4-methylamphetamine is associated with 
anorectic effects, hypertension, palpitations, headache, 
anxiety, insomnia, abdominal pain, hallucinations, paranoia, 
depression, nausea and vomiting.
A total of 20 non-fatal cases of acute 4-methylamphetamine 
toxicity or detection of 4-methylamphetamine in drug-related 
offences have been reported from five Member States. 
However, limited clinical detail is available in most of these. 
There is only one published case report of stimulant-like 
toxicity where 4-methylamphetamine has been identified; 
however, it is not possible to determine the significance of this 
as another drug was also detected (4-methylmeth-
amphetamine (2)) and the patient had consumed alcohol.
The first death where 4-methylamphetamine was detected 
was from the United Kingdom in October 2010. To date, there 
have been a total of 21 deaths from four Member States 
(Belgium, Denmark, the Netherlands and the United Kingdom) 
where 4-methylamphetamine alone or in combination with 
one or more other substance has been detected in post-
mortem samples. Based on the information available it is not 
possible to determine the significance of the detection of 
4-methylamphetamine in relation to the actual cause of death. 
There have been no reports of 4-methylamphetamine related 
deaths from other Member States, Croatia, Turkey and 
Norway.
In conclusion, 4-methylamphetamine is a synthetic 
phenethylamine stimulant. It is a ring-methylated derivative of 
amphetamine. There have been seizures from 15 Member 
States and two other countries that report to the EMCDDA. 
However, there is limited evidence of widespread use of 
4-methylamphetamine within Europe. There have been 21 
reported deaths potentially related to 4-methylamphetamine 
from four Member States. Seizure and exposure data 
suggests that people are likely to encounter 
4-methylamphetamine when attempting to source or use 
amphetamine (‘speed’). The published pharmacodynamic 
data suggests that 4-methylamphetamine has a similar 
pattern of toxicity to amphetamine. Overall, the prevalence of 
(2) N,p-dimethylamphetamine.
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FIGURE 1
The molecular structure, formula and weight of 
4-methylamphetamine. Asterisk indicates chiral centre
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 salt, i.e. Aptrol, see below).
Identification and analytical profile
4-Methylamphetamine gives a positive reaction for the 
Marquis reagent (orange changing to red); the Mecke reagent 
(yellow); the Mandelin reagent (brown); there is no colour 
reaction in the nitroprusside field test (Cordova, 1974; Soine et 
al., 1992; Bruijns, 2011).
Analysis using gas chromatography (GC) coupled with mass 
spectrometry (MS) is straightforward. Though the 2-, 3- and 
4-isomers have virtually identical MS spectra, they can be 
distinguished based on their GC retention time (Bailey et al., 
1974; Davis et al., 2012). The infrared and nuclear magnetic 
resonance spectra of these positional isomers also differ 
(Bailey et al., 1971; Bailey et al., 1974; Bailey & Legault, 1981; 
Border et al., 1993).
Mass spectral data for 4-methylamphetamine (m/z): 149, 44 
(Electron Ionisation / EI spectrum base peak), 150 (M+H+ , 
base peak), 148 (weak); 133 (Chemical Ionisation / CI 
spectrum base peak) (Bailey et al., 1974; Saferstein et al., 
1974; Brettell, 1983; Westphal et al., 2011; Davis et al., 2012; 
Strano-Rossi et al., 2012).
Selective liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) method for the analysis of 
4-methylamphetamine in saliva has been developed  
(Strano-Rossi et al., 2012).
Immunoassay field tests for amphetamines are likely to give a 
positive reaction with 4-methylamphetamine (Bal et al., 1989), 
although formal studies have not been published.
Physical description
The free base of 4-methylamphetamine is a nearly colourless 
liquid with an amine-like odour. Its boiling point is 222–224 ºC 
at atmospheric pressure (Nabenhauer, 1941) and 103–105 ºC 
TABLE 1
Chemical Abstract Service (CAS) Registry Numbers for 
4-methylamphetamine
CAS Registry Numbers Variant
64-11-9 unspecified amine
22683-78-9 (±) racemic amine
41632-56-8 HCl salt
878794-34-4 bisulfate
50650-74-3 sulfate as in Aptrol
788775-45-1 (R)-(–) enantiomer amine
81601-14-1 (S)-(+) enantiomer amine
81601-12-9 (R)-(–) enantiomer HCl salt
81601-11-8 (S)-(+) enantiomer HCl salt
4-Methylamphetamine is also known by its code names: pTAP 
(from para-tolylaminopropane); PAL-313; 4-MeA; 4-Me-PIA 
(thought to stand for 4-methylphenylisopropylamine); and 
PmeA. The often-used ‘4-MA’ abbreviation should be avoided 
because this can also denote para-methoxyamphetamine 
(also known as PMA) (Shulgin et al., 2011: 267). It is also 
important to distinguish 4-methylamphetamine from the 
substance commonly known as methamphetamine (’meth’), 
which is correctly called N-methylamphetamine.
4-Methylamphetamine contains an asymmetric carbon 
(Figure 1). Although analytical data are lacking, 
4-methylamphetamine sold on the illicit drug market is 
presumed to be a racemic mixture since the separation of the 
R and S enantiomers is costly. Known positional isomers of 
4-methylamphetamine are 2-methylamphetamine (also known 
as ‘ortetamine’) and 3-methylamphetamine. The N-methyl 
derivative of 4-methylamphetamine as well as several ring and 
side-chain homologues, including ring-substituted di- and 
trimethyl, 4-ethyl, 4-propyl and 4-isopropyl, and side-chain 
homologues have been described (Nabenhauer, 1941; 
Rosenmund & Karg, 1942; Schnider, 1945; Marsh & Herring, 
1950; Holland et al., 1963; Bailey et al., 1974; Bal et al., 1989; 
Glennon et al., 1992; Arnold et al., 1995; Davis et al., 2012). 
Notable among these is 3,4-dimethylamphetamine, or 
‘xylopropamine’ (Perhedrin, Esanin), that was studied in the 
1950s as an experimental appetite suppressant possessing 
analgesic and anti-inflammatory properties as well (4). The 
higher homologue, N-methyl-1-(4-pentylphenyl)propan-2-
amine (amfepentorex) was marketed as an appetite 
suppressant in France in the 1970s (5).
(4) http://www.chemspider.com/Chemical-Structure.24901
(5) http://www.chemspider.com/Chemical-Structure.64893
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Methods and chemical precursors used for the manufacture of 
4-methylamphetamine
The synthesis of 4-methylamphetamine requires similar 
equipment and chemical expertise to that needed for the 
production of other amphetamines. Most published methods 
for the synthesis of 4-methylamphetamine rely on the 
reductive amination of 4-methylbenzyl methyl ketone 
(4-methyl-BMK) (11) precursor and use of the Leuckart 
reaction (Allen & Cantrell, 1989). The reactions are feasible in 
an amateur laboratory setting and do not require 
sophisticated equipment.
In the first reported synthesis of 4-methylamphetamine 
published in 1938 by Jacobsen et al., ‘p-Toluylacetoxim’ was 
reduced by sodium amalgam to produce 4-methyl-
amphetamine. An independent patent filed in the same year 
describes the synthesis of 4-methylamphetamine based on 
the Leuckart method (Nabenhauer, 1941). The key precursor in 
both procedures is 4-methyl-BMK.
Alternative synthetic routes have also been described in the 
literature. These include using 4-methylbenzaldehyde 
(p-tolualdehyde) and nitroethane as starting materials 
(Henry-variant of the Knoevenagel condensation) and 
reduction of the resultant nitrostyrene with lithium aluminium 
hydride (LiAlH4) (Bailey et al., 1971; Moed et al., 1955; Muñoz 
et al., 2011; Davis et al., 2012).
4-Methylamphetamine has also been prepared by alternative 
synthetic routes (Brown, 1990; Gajda et al., 1997; Wagner et 
al., 2003). In theory, 4-methylamphetamine could also be 
synthesised by reductive deoxygenation from the 
corresponding cathinone derivative (4-methylcathinone) but 
this route has not been explored (12). Methods providing 
enantiomerically enriched 4-methylamphetamine are also 
known (Terent’ev & Potapov, 1956; Marco et al., 1987; Chen et 
al., 2009; Muñoz et al., 2011).
Although it is not clear by what method(s) 4-methyl-
amphetamine presently on the illicit market is actually 
manufactured, the available information suggests that 
4-methyl-BMK is one of the precursors. This ketone can be 
potentially used in general organic synthesis; it appears to be 
commercially available and is not under international control. 
As part of the data collection exercise conducted by the 
EMCDDA for the Joint Report (EMCDDA–Europol, 2012), 
websites were identified that sold 4-methyl-BMK. Quotations 
were requested for 1 or 10 kg of 4-methyl-BMK on lookchem.
com or directly from advertisers found on the Internet. This 
resulted in dozens of email responses from companies 
(11)  Other chemical names are 4-methylphenylacetone and 1-(4-methylphenyl)
propan-2-one. The CAS Registry Number for this ketone is: 2096-86-8.
(12) Other synthetic methods can also be envisaged (Soine, 1986).
at 10 mmHg pressure (Moed et al., 1955) (6). It is typically a 
solid salt form that is present in in seized and collected 
samples (7). The melting point of the water-soluble 
hydrochloride salt of 4-methylamphetamine is 158–159 ºC 
(Jacobsen et al., 1938), while the sulfate melts at 263 ºC with 
decomposition (Cordova, 1974). Both salts are white or lightly 
coloured crystals. Some websites listed chemical suppliers 
that could purportedly offer 4-methylamphetamine for sale; 
however, it is unknown what salt form is being offered.
4-Methylamphetamine has predominately been seized in 
powder and paste form, but liquids containing the substance 
have occasionally been encountered. Powders and the paste 
forms in which 4-methylamphetamine was identified typically 
also contained amphetamine and caffeine in varying ratios. 
Tablets and a solution (8) of the drug have also been seized; in 
some cases these also contained amphetamine and/or 
caffeine. In one case from 2009 the tablets were in 
commercial packaging that was labelled as an ‘ephedrine 
weight loss’ ‘dietary supplement’ (reported to be sold on the 
Internet, see Section A1.2.).
Analytical reports of seized, collected and biological samples 
of 4-methylamphetamine have not indicated the presence of 
other positional isomers.
As previously noted, no data are available on the enantiomeric 
composition of 4-methylamphetamine found in seizures, 
collected samples or biological samples (9). Similarly, it is 
unknown what enantiomeric form is purportedly offered by 
websites listing chemical suppliers of the drug.
Analytical reference samples of high purity are commercially 
available (10).
(6)  A single paper (Jacobsen et al., 1938) gives a melting point of ‘90–91 ºC’ for 
the substance they prepared; however, this value refers to the oxime 
precursor rather than to the amine product.
(7)  For the sake of brevity, the term ‘4-methylamphetamine’ is used throughout 
the text although it is the hydrochoride or sulfate salt that is seen in seizures 
and collected samples. For methodological reasons, and because 
4-methylamphetamine is frequently mixed with other salt-forming stimulants, 
the inorganic acid is usually not specified by forensic laboratories that analyse 
samples.
(8)  Germany reported a seizure of a nasal spray that contained a colourless, clear 
liquid containing amphetamine, 4-methylamphetamine and caffeine. As 
hydrochlorides, the amphetamines are readily water-soluble and it is possible 
that the spray was home-made from a powder or paste.
(9)  Published biological studies, including toxicological ones, have used the 
racemic mixture. It is not known whether there are differences between the 
pharmacology of 4-methylamphetamine enantiomers.
(10)  An example of a supplier of pure 4-methylamphetamine HCl for use as a 
reference standard is LGC Standards, https://www.lgcstandards.com/
epages/LGC.sf/en_GB/?ObjectPath=/Shops/LGC/Products/NMIAD895
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been characterized (Błachut et al., 2011; Westphal et al., 
2011). The impurity profile of a sample analysed in Germany 
indicates that amphetamine and 4-methylamphetamine could 
have been manufactured in the same batch: in addition to the 
typical ‘homodimers’ of the two amphetamines, that is 
N,N-di-(β-phenylisopropyl)amine (DPIA) and N,N-di-[β-(4-
methylphenyl)isopropyl]amine (D4MPIA), a ‘mixed amine’ or 
‘heterodimer’ formed either from BMK and 4-methyl-
amphetamine or from 4-methyl-BMK and amphetamine during 
the reaction was also detected. This indicates the 
simultaneous presence of the two ketone precursors in the 
reaction mixture (Westphal et al., 2011). The pharmacology 
and toxicology of D4MPIA dimers are unknown (see Ketema et 
al., 1990 for information on DPIA).
Caffeine, though not an ‘impurity’ because it is added 
intentionally, was found to be present in many seized and 
collected samples. Some samples have been found to contain 
ephedrine, MDMA, PMA and/or other phenethylamine 
derivatives. Caffeine is a typical adulterant observed in 
amphetamine samples.
For most seizures reported to the EMCDDA and Europol, the 
ingredient composition has not been quantified. For example, 
in a multi-kilogram seizure in the United Kingdom, the powder 
contained amphetamine (as the main identified psychoactive 
component estimated to be 14 %), 4-methylamphetamine 
(present in a lower concentration), with a substantial 
proportion of composition of the powder unspecified (Section 
C). Adulteration of some products with paracetamol has also 
been noted (for details on seizures see Section C).
In the early occurrences of 4-methylamphetamine in the 
United States of America in the 1970s, magnesium sulfate 
was identified as an adulterant (Cordova, 1974). This inorganic 
material is unlikely to be detected in forensic laboratories due 
to the reliance on standard techniques such as Infrared 
Spectroscopy or Gas Chromatography-Mass Spectrometry.
A1.2. Physical/pharmaceutical form
According to analytical evidence obtained so far, 
4-methylamphetamine most frequently occurs in mixtures 
containing other psychoactive substances in varying ratios 
(see above). Seizures in Europe indicate that 4-methyl-
amphetamine is trafficked on a multi-kilogram scale as 
powder, paste or liquid (Section C) having various colours 
(white, off-white, yellow, brown or pink). 4-Methylamphetamine 
has also been detected in tablet form on the illicit market, as 
noted in the Netherlands and Czech Republic, and in a 
commercial ‘weight loss’ ‘dietary supplement’ product seized 
by customs in Norway. In the latter, tablets from a product 
called ‘Green Stinger’ were analysed and found to contain a 
detailing the price per kilogram, as well as information on 
payment, shipping, delivery and/or purity. Typically, the price 
for 4-methyl-BMK ranged from USD 180 to 300 per one kg. 
The majority of the price quotations appear to originate from 
companies based in China.
In some of the seized samples, detectable amounts of 
4-methyl-BMK and benzyl methyl ketone (BMK) (13) have been 
found. This suggests that 4-methylamphetamine and 
amphetamine may have been synthesised subsequently in the 
same (and therefore un-cleaned) reaction vessel or 
simultaneously in the same batch from the mixture of the 
respective precursors (see ‘typical impurities’, below). Studies 
conducted on two samples containing 4-methylamphetamine 
seized by police in Ireland (Power et al., 2013) showed that the 
major impurities were analogous to those found in the 
manufacture of amphetamine and N-methylamphetamine by 
the Nagai route using ephedrine and the Leuckart route using 
BMK.
According to information from Dutch police (Section F), there 
are indications that some producers believe that they are 
attempting to produce amphetamine using the precursor 
BMK, when they are actually using 4-methyl-BMK and 
subsequently producing 4-methylamphetamine.
A recent report (Hao et al., 2007) describing the GC–MS 
spectrometry-based identification of 4-methylamphetamine in 
the essential oil of a tropical weed is most probably 
erroneous (14).
Typical impurities encountered in seized samples
In general, the analyses of seized samples containing 
4-methylamphetamine revealed great variation in the 
composition. 4-Methylamphetamine is uncommon as a pure, 
unmixed material. Of note is that amphetamine is the most 
common co-occurring substance. It is not clear whether such 
mixtures of these two amphetamines are produced 
deliberately or accidentally. In Belgium and the Netherlands it 
has been hypothesised that the presence of 4-methyl-
amphetamine in amphetamine (’speed’) samples (Section F) 
is probably due to a change in the precursors used for the 
illicit synthesis of amphetamine. For example, it may be the 
case that a mixture of BMK and 4-methyl-BMK is being used 
by illicit labs that have imported the precursors from China/
Russia for amphetamine synthesis (Blanckaert, 2012). 
Impurities characteristic to the Leuckart method have recently 
(13)  Benzyl methyl ketone (BMK), also known as phenylacetone or phenylpropan-
2-one (P2P), is the main precursor used in the manufacture of amphetamine 
and methamphetamine.
(14)  The paper, referenced in Chemical Abstracts, is in Chinese and the abstract 
does not give sufficient details of the analytical results. Attempts to obtain a 
full copy of the paper have been unsuccessful so far. Earlier reports on 
amphetamine-type compounds in plants have not been confirmed.
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the second user report to Shulgin, the doses reported were 
160 mg for oral use and 80–120mg for intramuscular injection 
(Shulgin et al., 2011: 276). Information provided by France that 
was collected from drug user forums suggested oral doses of 
10–300 mg. Overall, since it appears that most use of 
4-methylamphetamine occurs when users are attempting to 
purchase amphetamine (‘speed’) it is likely that the single use 
doses of 4-methylamphetamine are similar to those for 
amphetamine.
I  A2. Pharmacology, including pharmacodynamics and pharmacokinetics
Pharmacodynamics
There are a number of animal models that have investigated 
the pharmacodynamic effects of 4-methylamphetamine.
In a series of experiments in different animal models the 
effects of 4-methylamphetamine were compared to 
amphetamine (Marsh & Herring, 1950). 4-Methylamphetamine 
(1:40,000) produced a 30 % decrease in tone in rabbit jejunum 
compared to a 10 % decrease seen with the same amount of 
amphetamine. 4-Methylamphetamine produced a similar 
bronchodilator effect to amphetamine in a guinea pig tracheal 
chain model: 13 mm decrease in tone for 
4-methylamphetamine (1:4000) vs. 15 mm decrease in tone 
for amphetamine (1:4000). A dose of 15 mg/kg of 
4-methylamphetamine was required to produce the same 
stimulant effects as 2 mg of amphetamine in rats. 4-Methyl-
amphetamine was shown to have less anorectic effect than 
amphetamine in dogs, with an average time following 1 mg/kg 
administration to begin eating of 65 minutes and 25 minutes 
respectively, and to complete eating of 30 minutes and 20 
minutes respectively. This finding was confirmed in a 
standardised deprivation-induced fluid consumption test 
using rats as experimental animals where the most effective 
anorectic agent in reducing water intake was 
dextroamphetamine followed by 4-methylamphetamine and 
fenfluramine (Zabik et al., 1984).
The effects of 4-chloroamphetamine, 4-fluoroamphetamine 
and 4-methylamphetamine have been compared in a whole 
rat model at intra-peritoneal doses of 5 mg/kg and 10 mg/kg 
(Beaton et al., 1968). 4-Methylamphetamine was reported to 
be the least active of the three compounds tested, with 5 mg/
kg causing ‘low dose stimulant’ and 10 mg/kg causing ‘high 
dose stimulant’ effect. All of the rats treated with 
4-fluoroamphetamine and 4-chloroamphetamine at a dose of 
10 mg/kg died between 6 and 20 hours after administration; 
although not explicitly stated, it appears that none of the rats 
treated with 4-methylamphetamine died.
number of phenethylamines, including 4-methylamphetamine. 
Germany reported a seizure of a nasal spray containing a 
colourless solution of 4-methylamphetamine, amphetamine 
and caffeine.
A1.3. Route of administration and dosage
There are only two user reports relating to the possible use of 
4-methylamphetamine. In the first of these, an individual is 
reported to have used 10–50 mg of product that may have 
contained ‘4-methylamphetamine’ or ‘4-methylmeth-
amphetamine’ (15) (Drugs Forum, 2008). No information was 
provided on the nature of the product or the route of 
administration. In the second user report to Shulgin et al. 
(2011: 276) the doses reported were 160 mg for oral use and 
80–120 mg for intramuscular injection. There appears to be 
little or no further information on other popular drug user 
discussion forums or drug-orientated websites such as Erowid.
As discussed in Section C and Section D, it appears that the 
majority of exposures to 4-methylamphetamine occur where 
individuals have attempted to purchase and use amphetamine 
(’speed’) in powder or paste form. It is likely, therefore, that 
4-methylamphetamine will be used by similar routes as 
amphetamine, namely: by oral ingestion, nasal insufflation, 
intramuscular injection, intravenous injection and rectal 
insertion. As 4-methylamphetamine is frequently encountered 
in powder/paste form there is the potential that nasal 
insufflation is a common route of use. However, it is not 
possible to be certain of this as there is limited information 
available from user forums and other sources. Extrapolating 
from amphetamine use, oral ingestion is likely to be by use of 
the powder directly (for example by wrapping in cigarette or 
other paper (‘bombing’) prior to swallowing), or swallowing 
tablets or capsules. It is likely that the powder can also be 
dissolved in water/other liquids. There is one user report of 
intramuscular injection of 4-methylamphetamine (Shulgin et 
al., 2011: 276).
Since there is little or no information on Internet drug user 
discussion forums or in the published scientific and grey 
literature on the doses of 4-methylamphetamine, it is not 
possible to determine with certainty those taken by users. 
Furthermore, there are no data from the non-fatal 
intoxications and fatal cases related to 4-methylamphetamine 
(summarised in Section D) on the doses of 4-methyl-
amphetamine used. The only information is from two user 
reports. In the first of these, on a discussion forum, the 
individual reported using 10–50 mg of a product that was 
thought to possibly contain 4-methylamphetamine; the route 
of use was not stated in this report (Drugs Forum, 2008). In 
(15) N,p-dimethylamphetamine.
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amphetamines such as 2- and 4-chloroamphetamine (dose 
giving a +3 response: 24 µmol/kg). Finally the effects of the 
compounds to potentiate the ‘5-HTP [5-HT] (5-hydro-
xytryptophan) syndrome’, where administration of 5-HT is 
associated with head-twitches, tremor and abduction of hind 
legs, and suggests that the compound inhibits uptake of 
serotonin (5-HT), were compared. 4-Methylamphetamine was 
shown to strongly potentiate the 5-HT syndrome, suggesting it 
has more potent activity in inhibiting 5-HT uptake than 
dl-amphetamine and 2-, 3- and 4-chloroamphetamine.
The effects of 4-methylamphetamine on dopamine, 
noradrenaline and 5-HT release have been studied on rat 
caudate homogenates tissue (Wee et al., 2005). The EC
50
 for 
dopamine and noradrenaline release for 4-methyl-
amphetamine and amphetamine were comparable: [dopamine 
EC
50
, 4-methylamphetamine: 44.1 ± 2.6 nM; amphetamine: 8.0 
± 0.43 nM. Noradrenaline EC
50
, 4-methylamphetamine: 22.2 ± 
1.3 nM; amphetamine 7.2 ± 0.44 nM]. However, with respect to 
5-HT, 4-methylamphetamine was significantly more potent 
compared to amphetamine: EC
50
 for 4-methylamphetamine 
was 53.4 ± 4.1 nM compared to 1756 ± 94 nM for 
amphetamine. In this study, self-administration of 4-methyl-
amphetamine was compared with other amphetamine 
analogues including amphetamine, 3-methylamphetamine, 
4-fluoroamphetamine and 3-fluoroamphetamine. 
4-Methylamphetamine was the least likely of all the 
compounds to cause self-administration. The authors 
concluded that there is a decrease in the reinforcing potency 
and efficacy of a ring-substituted amphetamine when it has 
greater 5-HT releasing potency compared to dopamine 
releasing potency.
Rats were treated with 0, 2, 4, 8 and 16 µmol/kg of 
4-methylamphetamine, amphetamine and other ring-
substituted amphetamines (Wellman et al., 2009). All 
compounds were noted to reduce food intake in a dose-
dependent manner. However, 4-methylamphetamine was 
noted to cause no significant increase in forward locomotor 
activity, compared to other analogues including 3-fluoro-
amphetamine and 1-naphthyl-aminopropane, which in 
previous studies have been shown to have potent 
noradrenaline and dopamine releasing activity but minimal 
5-HT releasing activity.
In a squirrel microdialysate model, administration of 
4-methylamphetamine was shown to not significantly increase 
extra-cellular dopamine concentrations compared to placebo 
and it did not increase behavioural stimulant effects (Kimmel 
et al., 2009).
The effects of 4-methylamphetamine on extracellular 
dopamine and 5-HT concentrations were investigated in 
microdialysis of rat nucleus accumbens (Baumann et al., 
Using a homogenate of whole rabbit adrenal glands the 
effects of 4-methylamphetamine on phenethanolamine 
N-methyltransferase (PNMT), responsible for the conversion 
of noradrenaline into adrenaline, have been studied (Fuller et 
al., 1971). The inhibition of this enzyme by 4-methyl-
amphetamine was reported to be comparable to that seen 
with amphetamine and the authors concluded that there was 
reasonable agreement between the expected inhibition of 
PNMT compared to that actually seen.
Although about five times less stimulatory in rats in vivo, 
4-methylamphetamine was more potent than amphetamine in 
inhibiting rodent brain monoamine oxidase (MAO) enzymes 
leading to elevated dopamine, and, in particular, serotonin 
levels both in vitro and in vivo (Fellows & Bernheim, 1950; 
Ross et al., 1977) (16).
In receptor binding studies, 4-methylamphetamine showed 
low affinity to 5-HT
1C
 and 5-HT
2A
 serotonin receptors (K
i
 > 
10,000 nM for either receptor) while for 2,5-dimethoxy-4-
methylamphetamine (DOM) the respective K
i
 values were 193 
and 100 nM indicating that the incorporation of 2- and 
5-methoxy groups greatly enhances serotonin receptor-
related hallucinogenic activity (Glennon et al., 1992; see also 
Shannon et al., 1984).
In a mouse model of motor activity, the effects of 
4-methylamphetamine were compared to amphetamine and 
other ring substituted amphetamines (Ögren & Ross, 1977). 
The drugs were administered intra-peritoneally and motor 
activity was measured over a 10 minute period half an hour 
after drug administration. 4-Methylamphetamine increased 
motor activity: 38 µmol/kg increasing muscle activity by 
200 %; the same magnitude of increase in muscle activity was 
seen with 16 µmol/kg for amphetamine and 24 µmol/kg for 
both 2- and 3-chloroamphetamine. The authors compared the 
ED
200
 (the dose required to cause a 200 % increase in motor 
activity) to previously published EC
50
 for the inhibition of 
noradrenaline uptake (Ross, 1977). The ratio for 
4-methylamphetamine was 0.7, suggesting that the increase 
in motor activity was predominately due to inhibition of 
noradrenaline uptake. The authors then compared the ability 
of drugs to potentiate the ‘L-Dopa syndrome’ (piloerection, 
irritability, reactivity, jumping, squeaking and fighting following 
administration of L-Dopa), where it is known that drugs that 
inhibit the uptake of noradrenaline potentiate the L-Dopa 
syndrome. 4-Methylamphetamine was the most potent at 
potentiating this syndrome (dose giving a +3 response: 
7 µmol/kg) compared to amphetamine (dose giving a +3 
response: 14 µmol/kg) and the other ring-substituted 
(16)  This finding of MAO inhibition was also predicted by computation analysis as 
part of the EMCDDA-commissioned study ‘Computational analysis on the 
pharmacology of 4-methylamphetamine’ (September 2012), Annex 2 of this 
publication.
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β-hydroxylation of the isopropylamine chain leading to the 
known norephedrine homologue (Ueda et al., 1956).
Furthermore, oxidative deamination of 4-methylamphetamine 
would give rise to the corresponding ketone (4-methyl-BMK).
In subsequent Phase II metabolic steps, excreteable 
derivatives may be formed by conjugation (e.g., 
glucuronidation or sulfation) but again such derivatives of the 
parent drug have not been described so far.
The pharmacological properties of the putative metabolites of 
4-methylamphetamine are unknown.
In addition to the potential drug interactions noted earlier 
(such as with amphetamine and/or caffeine), the overall 
human pharmacology and toxicity of 4-methylamphetamine 
may also be influenced by its metabolites. Gender differences 
and genetic factors may influence the pharmacokinetics of 
4-methylamphetamine, in particular its metabolism.
Pharmacokinetics
There are no data available from animal studies in the 
published or grey literature on the pharmacokinetics of 
4-methylamphetamine. One volunteer study in the 1950s 
investigated the clinical features associated with 
4-methylamphetamine use. Here the effects of 
4-methylamphetamine and other ring-substituted 
amphetamines (such as 2- and 3-methylamphetamine) were 
compared to amphetamine (Marsh & Herring, 1950). Fourteen 
male volunteers were administered 0.5 mg/kg amphetamine. 
Of these, six had systolic blood pressure increases of a 
maximum of 22–28 mmHg. These were then selected for 
further testing performed at three or four day intervals and 
administered amphetamine in doses of 0.25, 0.5 and 0.75 mg/
kg and the ring-substituted amphetamines given in doses of 
0.5, 0.75, 1.0, 1.5 and 2.0 mg/kg. 4-Methylamphetamine 
induced anorectic effects lasted 6–10 hours after 1.5 mg/kg 
4-methylamphetamine and severe hypertension lasted 20–30 
minutes after 2.0 mg/kg of 4-methylamphetamine (Marsh & 
Herring, 1950). There is limited information available from user 
reports or Internet drug user discussion forums to be able to 
determine pharmacokinetic parameters such as time to onset 
of desired / adverse effects or duration of action of 
4-methylamphetamine. The only information is provided in a 
personal communication to Shulgin et al., in which a user 
reported ‘psychedelic effects’ with a ‘plateau at two hours, and 
baseline at four hours’ after self-reported use of oral (160 mg) 
and intramuscular (80–120 mg) 4-methylamphetamine 
(Shulgin et al., 2011: 276).
2011). Animals were administered 1 mg/kg 
4-methylamphetamine intravenously at time 0, followed by 
3 mg/kg intravenously at time 60 minutes. A number of 
ring-substituted amphetamines were studied including 
3-fluoroamphetamine, 4-fluoroamphetamine and 
3-methylamphetamine, and it was noted that 
4-methylamphetamine was the least potent at increasing 
extracellular dopamine concentrations. Conversely, 
4-methylamphetamine was the most potent at increasing 
extracellular 5-HT concentrations. 4-Methylamphetamine was 
shown to be the least potent at increasing locomotor activity, 
but had comparable effects in terms of stereotypical 
behaviour effects. The authors concluded that changes in 
5-HT concentrations correlated with stereotypical behaviour 
effects, whereas changes in dopamine concentrations 
correlated with both stereotypical behaviour and ambulation 
(locomotor activity). There is the possibility that drugs such as 
4-methylamphetamine which, as discussed above, has a 
predominant effect on 5-HT rather than dopamine, may 
ameliorate some of the stimulatory and psychoactive effects 
of amphetamine leading to repeated dosing.
It is worthy of note that no studies involved the co-
administration of 4-methylamphetamine and amphetamine, 
the most prevalent situation observed in the illicit market, 
therefore there are no data on possible synergistic or other 
effects. Finally, it must be noted that pharmacological 
experiments carried out to date used the racemic mixture of 
4-methylamphetamine. The pharmacokinetics and 
pharmacodynamics of the pure R- or S-stereoisomers may be 
different and it must be borne in mind that the 
stereochemistry of seized and collected samples is not 
known.
There is no published information on the biotransformation 
(metabolism) of 4-methylamphetamine in animals or humans. 
It is reasonable to assume, however, that metabolism follows 
the biochemical pathways established for structurally related 
substances. These include pyrovalerone derivatives and 
mephedrone (Michaelis et al., 1970; Cho & Kumagai, 1994; 
Anderson, 1999; Dalmadi et al., 2003; Springer et al., 2003; 
Peters et al., 2008; Pedersen et al., 2012).
During the initial oxidative Phase I metabolism, side-chain 
hydroxylation can occur at the 4-methyl group or at the 
isopropylamine moieties. The former provides 
4-(hydroxymethyl)amphetamine as a postulated 
metabolite (17). The other potential biotransformation step is 
(17)  For amphetamine, hydroxylation of the aromatic ring at position 4 is possible 
and the resulting 4-hydroxyamphetamine (paredrine) is pharmacologically 
active (adrenergic). Such catecholamine-like 4-hydroxymethylated structural 
moietes can be found in adrenergic antiasthmatic bronchodilators, including 
albuterol. 
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substance will be developed and/or commercialised as a 
medicinal product.
There is no information that 4-methylamphetamine is currently 
used in the manufacture of any medicinal product in the 
European Union. However, in the absence of a European Union 
database on the synthetic routes of all medicinal products this 
information cannot be verified. There is no marketing 
authorisation (existing, ongoing or suspended) for 
4-methylamphetamine neither in the European Union nor in 
the Member States that responded to the request for 
information from the European Medicines Agency (EMCDDA–
Europol, 2012).
As discussed, 4-methylamphetamine has recently been used 
as a pharmacological tool to study in vitro and in animal 
models the relationship between the monoamine 
neurotransmitter-releasing properties and the behavioural 
effects of amphetamine-type stimulants (Wee et al., 2005; 
Rothman et al., 2006; Wellman et al., 2009). In a recent 
experiment with squirrel monkeys, 4-methylamphetamine 
failed to elicit behavioural-stimulant effects and it was 
suggested by the authors that it may have potential in the 
treatment of cocaine dependence (Kimmel et al., 2009).
I  Section B. Dependence and abuse potential
I B1. Animal in vivo and in vitro data
A study by Wee et al. (2005) compared self-administration of 
4-methylamphetamine with other amphetamine analogues 
including amphetamine, 3-methylamphetamine, 
4-fluoroamphetamine and 3-fluoroamphetamine. 
4-Methylamphetamine was the least likely of all the 
compounds to cause self-administration in both a fixed-ratio 
schedule and a progressive ratio schedule, as shown in 
Figures 2 and 3.
I A3. Psychological and behavioural effects
There are no published formal studies assessing the 
psychological and/or behavioural effects of 
4-methylamphetamine in humans.
In model experiments with cats, rabbits and rats, the 
pharmacological spectrum of 4-methylamphetamine was more 
LSD-like than that of amphetamine, though it was much less 
active than 2,5-dimethoxy-4-methylamphetamine (DOM), the 
prototypical hallucinogen used in the study (Aldous et al., 1974).
The user report from the Internet discussion forum noted in 
Section A1.3 suggests that the undesired psychological and 
behavioural effects related to 4-methylamphetamine use 
included ‘headache, nervousness and stimulation resembling 
ephedra’ (Drugs Forum, 2008). There is no information as to 
whether there was concomitant use of other substances that 
could have contributed to the unwanted effects described. 
Additionally, since this is a user report, there is no analytical 
confirmation that the individual had indeed used 
4-methylamphetamine; the report suggests that it may have 
been either ‘4-methylamphetamine’ or 
‘4-methylmethamphetamine’.
I A4. Legitimate uses of the product
4-Methylamphetamine is used as an analytical reference 
standard and in scientific research (which is often in 
combination with amphetamine and related compounds, 
many of which are under international control). There are no 
other indications that 4-methylamphetamine may be used for 
any other legitimate purposes. There are no known uses of 
4-methylamphetamine as a component in industrial, cosmetic 
or agricultural products.
Racemic 4-methylamphetamine, known by its trade name 
Aptrol, underwent human clinical trials as an anorectic agent 
in the 1950s (Section D). The proposed daily dosage for Aptrol 
was 25 or 50 mg three times a day. However, its development 
and marketing was abandoned for unknown reasons and it 
was never made commercially available.
Claims have been made in the patent literature on the use of 
4-methylamphetamine as a potential medicine. These include 
the treatment of stimulant addiction, as an analgesic, and as 
an antiparkinson agent (Caron et al., 2007). Claims have also 
been made for its use as an intermediate in the synthesis of 
potential medicines (Ferris, 1986). It should be noted, 
however, that patents may contain broad claims (for example, 
the use of ‘Markush structures’), and the inclusion of a 
chemical structure in a patent does not imply that the 
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exposure to 4-methylamphetamine relates to individuals 
sourcing amphetamine (‘speed’) rather than 
4-methylamphetamine itself. Therefore, users are unlikely to 
report that the primary (or secondary) drug associated with 
their dependency is 4-methylamphetamine.
I Section C. Prevalence of use
In a historical context, 4-methylamphetamine has appeared 
sporadically on the illicit drug market. Its appearance was 
reported first from the United States of America in 1973 
(Keaton, 1973; Cordova, 1974) and later it was also detected 
in the United Kingdom (Bal et al., 1989). Internet searches for 
‘4-methylamphetamine’ found that the use and effects of the 
substance have been discussed by drug users from mid-2008, 
who note that it was ‘known in Russia and Ukraine’ (Bluelight, 
2008, 2009). Since the introduction of the European Union 
early-warning system in 1997, 4-methylamphetamine was first 
detected in Belgium in 2009, with formal notification to the 
EMCDDA on the 14 December 2009. There have been reports 
to the EMCDDA and Europol of seizures and collected 
samples of 4-methylamphetamine in 15 Member States as 
well as Croatia and Norway. In some of the seizures, the exact 
position of methyl group on the aromatic ring has not been 
identified and so it is not possible to be definitively certain that 
the substance was 4-methylamphetamine.
Most commonly in seizures and collected samples, 
4-methylamphetamine has been found together with 
amphetamine and caffeine (Table 2). 4-Methylamphetamine 
has been the only active substance in a seized sample in only 
a few cases. This has been the case in some of the samples 
seized in Belgium, Croatia, Denmark, France, Germany, 
Ireland, the Netherlands and Sweden. Generally the analyses 
have been qualitative and so the amount of 4-methyl-
amphetamine detected has not been reported and it is not 
possible to state the relative proportion of active ingredients 
in the seized products. In cases where the amount of 
4-methylamphetamine present is reported this has varied 
from a trace or minor component to a small number of reports 
in which 4-methylamphetamine is reported as a larger or main 
component of the mixture.
Seizures have varied in size from as small as 0.02 g (Germany 
in 2011) to 147 kg (France in 2012). Most commonly, these 
seizures have involved 4-methylamphetamine in powder or 
paste form (commonly white, white-yellow, off-white or yellow); 
there have also been reports of 4-methylamphetamine being 
seized in liquid (France, Germany, Sweden) and tablet (the 
Netherlands and Norway) form.
FIGURE 2
Self-administration under a fixed-ratio schedule (Wee et al., 
2005). Key: PAL-353: 3-fluoroamphetamine; PAL-303: 
4-fluoroamphetamine; PAL-314: 3-methylamphetamine; 
PAL-313: 4-methylamphetamine
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FIGURE 3
Self-administration under a progressive-ratio schedule (Wee 
et al., 2005). Key: PAL-353: 3-fluoroamphetamine; PAL-303: 
4-fluoroamphetamine; PAL-314: 3-methylamphetamine; 
PAL-313: 4-methylamphetamine
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I B2. Human data
There are no user reports or published cases in the scientific 
or grey literature describing the dependence or abuse 
potential for 4-methylamphetamine. Additionally, there have 
been no formal studies investigating the dependence and/or 
abuse potential of 4-methylamphetamine in humans. We are 
not aware of any reports from local, regional or national drug 
treatment agencies relating to 4-methylamphetamine 
dependence. It is possible that this is due to the fact that 
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TABLE 2
Details of the seizures and collected samples of 4-methylamphetamine reported to the EMCDDA and Europol. In a small number 
of cases the date listed may refer to the date the information was reported to EMCDDA
Year/ordered 
by country
Amount and details of the seizure/collected sample
Austria
2010 One yellow powder sample seized by police weighing approximately 2 kg, also containing amphetamine.
2011 Four yellow powder samples seized by police: 260 g, 50 g, 49 g and 4 g, all containing amphetamine.
2012 Four collected samples from a ‘party’ analysed on 14/04/2012. All samples had been sold as ‘speed’: one white paste-like powder 
(0.060 g) containing 4-methylamphetamine (24 mg/g), amphetamine (95 mg/g), ephedrine (16 mg/g) and caffeine (65 mg/g); one 
white powder ‘self-made’ (1.126 g) containing 4-methylamphetamine (16 mg/g), amphetamine (208 mg/g), caffeine (542 mg/g); one 
white powder (0.03 g) containing 4-methylamphetamine (4 mg/g), amphetamine (73 mg/g) and caffeine (145 mg/g); and one 
paste-like white powder (0.103 g) containing 4-methylamphetamine (19 mg/g), amphetamine (69 mg/g), ephedrine (27 mg/g) and 
caffeine (66 mg/g).
2012 Two collected samples from a ‘party’ analysed on 25/05/2012. All samples had been sold as ‘speed’: one white powder (0.69 g), 
containing 4-methylamphetamine (19 mg/g), amphetamine (67 mg/g) and caffeine (62 mg/g); and one white powder (0.19 g) 
containing 4-methylamphetamine (8 mg/g), amphetamine (34 mg/g), 4-methylethcathinone (40 mg/g), caffeine (384 mg/g), 
paracetamol (59 mg/g) and an unknown substance.
2012 A further 13 samples (weights unknown) analysed between July and September 2012 containing 4-methylamphetamine (trace to 
231 mg/g) and amphetamine (40–327 mg/g). One of these samples contained 4-methylamphetamine (231 mg/g) and 
amphetamine (647 mg/g).
2012 Several small seizures made by police. All weighed less than 1 g and contained 4-methylamphetamine, amphetamine and caffeine.
Belgium
2009 16 bags, each containing a piece of yellow paste in aluminium foil. Of these, nine bags contained approximately 5 g of paste, one bag 
39 g, six bags 70–80 g. Also contained 4-methyl BMK and ‘other by products’.
2010 Two seizures of 1.81 g powder also containing amphetamine and caffeine. 
2010 One seizure of 137 g paste also containing 4-methyl-BMK and caffeine.
2011 One report of powder found on a fatality containing 4-methylamphetamine (56 %), amphetamine (14 %) and caffeine (13 %).
2011 One report of powder found on a fatality also containing amphetamine and caffeine. 
2011 One report of powder found on an intoxicated patient containing 4-methylamphetamine (64 %), amphetamine (16 %) and caffeine 
(15 %); purchased as ‘Special K’ (street name for ketamine).
2011 Three powder samples for which two the purity is known (56 % and 64 %) also containing amphetamine and caffeine.
2011 One seizure containing: one plastic bag with 1.8 g of white-yellow powder; a brown leather ‘etui’ with six plastic bags: two containing 
white powder (0.5 g, 0.8 g); three containing yellow powder (0.7 g, 2.5 g, 1.3 g); and one containing white-yellow powder 1.8 g.
2011 Two powder seizures (unknown amount) also containing amphetamine and caffeine. 
2011 Two seizures of paste also containing caffeine and amphetamine: one seizure weighed 10.2 g; the second seizure was comprised of 
sachets weighing 10.5 g, 34.4 g and 100.5 g and bags ranging from 954.7 g to 990.5 g.
2011 Two seizures also containing caffeine, amphetamine, cannabinol and THC.
2012 One report of yellow-white powder in the possession of a patient (fatal case) that contained 4-methylamphetamine and 
amphetamine.
2012 One report of a powder in the possession of a patient (fatal case) that contained 4-methylamphetamine, amphetamine, caffeine and 
diphenylisopropylamine (DPIA).
2012 One seizure of 82 g of yellow paste containing 4-methylamphetamine (21 %) also containing amphetamine (13 %) and caffeine 
(16 %).
2012 One ‘pacson’ containing 1.4 g of yellow powder containing 4-methylamphetamine HCl (37 %) also containing amphetamine sulphate 
(23 %).
2012 In June, a syringe was analysed containing 4-methylamphetamine, amphetamine and caffeine (not quantified).
2012 A seizure of 179.6 g of powder was made by federal police services in June. Contents: caffeine (35 %), amphetamine-sulphate 
(21 %), 4-methylamphetamine (<1 %).
Bulgaria
No reports.
Cyprus
No reports.
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Year/ordered 
by country
Amount and details of the seizure/collected sample
Czech Republic
2012 One seizure in the second half of 2012 of several pieces of tablets. MDMA was the major component and 4-methylamphetamine 
was present in a small amount. Analytical data are not yet available.
Denmark
2010 One seizure of 1 g of white powder.
Estonia
No reports.
Finland
2011 32 seizures of powder totalling 1070 g, also containing amphetamine. Earliest case was seized 18 April 2011.
France
2009 One sample of a paste with a ‘strong smell’, also containing amphetamine, collected from a user.
2011 9 kg of liquid also containing amphetamine.
2011 81.7 kg of a white paste also containing amphetamine (19 %) and caffeine.
2012 147 kg of a paste (undefined colour) also containing amphetamine and caffeine; this is the largest seizure reported to the EMCDDA 
and Europol.
2012 42 kg of paste also containing amphetamine and caffeine.
No date Unknown quantity of yellow powder containing 4-methylamphetamine.
Germany
2010 938 g of white ‘amphetamine-like’ powder.
2010 3.29 g of a brown powder also containing amphetamine and caffeine.
2010 45.4 g also containing amphetamine and caffeine.
2010 744.5 g of a colourless moist substance also containing caffeine.
2010 0.342 g and 0.194 g of mixtures also containing amphetamine and caffeine.
2010 Four samples containing methylamphetamine (position of methyl group not identified) and other undefined active ingredients.
2010 652 g of a white moist cluster also containing amphetamine.
2011 8.7 g of a brown-yellow coloured substance also containing amphetamine and caffeine (exact position of methyl group in the 
methylamphetamine not identified).
2011 Seven samples totalling 240.4 g also containing amphetamine and caffeine.
2011 948.46 g of a mixture also containing amphetamine and caffeine (exact position of methyl group in the methylamphetamine not 
identified).
2011 Seizure of white powder (weight unknown) containing 4-methylamphetamine.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 10 kg of white powder also containing amphetamine, caffeine and traces of 4-methyl-BMK.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified). 
2011 27 g of amphetamine with traces of methylamphetamine (exact position of methyl group in the methylamphetamine not identified).
2011 1007.9 g amphetamine found to contain a small amount of 4-methylamphetamine.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 77 g of amphetamine with traces of methylamphetamine (exact position of methyl group in the methylamphetamine not identified).
2011 255.2 g of a mixture also containing amphetamine and caffeine.
2011 Two seizures totalling 2.49 g of a beige substance also containing amphetamine.
2011 1.46 g of a yellow substance containing amphetamine and caffeine.
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Year/ordered 
by country
Amount and details of the seizure/collected sample
2011 Nasal spray with colourless liquid also containing amphetamine and caffeine.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 Approximately 260 g of white substance filled into small plastic bags for sale also containing amphetamine, caffeine and lactose.
2011 4.5 g of amphetamine with traces of methylamphetamine (exact position of methyl group in the methylamphetamine not identified).
2011 6.23 g of a grey substance also containing amphetamine.
2011 1.1 g of a yellow substance also containing amphetamine and caffeine.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 77.6 g of a mixture also containing amphetamine and caffeine. The ‘relation’ between 4-methylamphetamine and amphetamine ‘was 
about 50 to 50’.
2011 554 g of amphetamine with traces of methylamphetamine (exact position of methyl group in the methylamphetamine not identified).
2011 Two seizures of 318.3 g also containing amphetamine and caffeine.
2011 22.9 g also containing amphetamine and caffeine.
2011 16 shrink-wrapped plastic bags each containing 1 kg of white substance (16 kg in total). All contained amphetamine and caffeine; an 
unknown number also contained 4-methylamphetamine.
2011 257.8 g also containing amphetamine, methoxyamphetamine and caffeine (exact position of methyl group in the 
methylamphetamine not identified).
2011 0.54 g of white substance also containing amphetamine and caffeine.
2011 Amphetamine samples (amount unknown) containing traces of methylamphetamine (exact position of methyl group in the 
methylamphetamine not identified).
2011 1.9 g of white substance also containing amphetamine and caffeine.
2011 8.8 g also containing amphetamine and caffeine (exact position of methyl group in the methylamphetamine not identified).
2011 0.6 g of white substance also containing caffeine and amphetamine.
2011 0.02 g of white substance also containing amphetamine, di-(beta-phenylisopropyl-)amine and caffeine.
2011 91 g of amphetamine with ‘smaller part’ of 4-methylamphetamine and caffeine.
2011 One plastic bag labelled ‘2.0g PEP’ and two bags labelled ‘1.2g PEP’ also containing caffeine (exact position of methyl group in the 
methylamphetamine not identified).
2012 Unknown amount of white powder also containing amphetamine, di-(beta-phenylisopropyl-)amine, caffeine, cocaine and THC.
2012 Analysis of forensic checks of amphetamine samples, amount unknown, contained traces of methylamphetamine (exact position of 
methyl group in the methylamphetamine not identified).
2012 2.22 kg of a mixture also containing amphetamine and 4-methoxyamphetamine.
2012 19.8 g of a mixture also containing amphetamine and caffeine.
2012 Approximately 90 g of 4-methylamphetamine (no further details available).
2012 19.7 g of 4-methylamphetamine ‘laced’ with caffeine and lactose.
2012 22.9 g of a mixture also containing amphetamine, 4-methoxyamphetamine and caffeine.
2012 41 g of a mixture also containing MDMA, amphetamine, 4-methoxyamphetamine and caffeine.
2012 51.63 g of white powder also containing amphetamine and caffeine (exact position of methyl group in the methylamphetamine not 
identified).
2012 Analysis of an amphetamine sample (amount unknown) contained traces of methylamphetamine (exact position of methyl group in 
the methylamphetamine not identified).
2012 76.4 g also containing amphetamine and caffeine.
2012 40 g of amphetamine with traces of methylamphetamine (exact position of methyl group in the methylamphetamine not identified).
2012 21.2 g of a mixture also containing amphetamine and caffeine (exact position of methyl group in the methylamphetamine not 
identified).
2012 0.15 g of a mixture also containing amphetamine and caffeine.
2012 42.5 g of 4-methylamphetamine ‘laced’ with caffeine.
2012 96.9 g of a mixture also containing amphetamine and caffeine.
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Year/ordered 
by country
Amount and details of the seizure/collected sample
2012 Analysis of an amphetamine sample (amount unknown) contained traces of methylamphetamine (exact position of methyl group in 
the methylamphetamine not identified).
2012 133.8 g of a white powder also containing caffeine.
Greece
No reports.
Hungary
2010 Two seizures: one of 21 g yellow powder containing 4-methylamphetamine; one seizure of nine packages, with a total of 1768 g of 
yellow powder also containing amphetamine (2–3 %) and caffeine. 4-Methylamphetamine was present in a similar concentration to 
amphetamine.
Ireland
2012 11.9 g of a yellow-orange waxy powder/paste.
2012 5.61 g of a white powder also containing amphetamine.
2012 487.807 g powder in 18 packs.
Italy
No reports.
Latvia
No reports.
Lithuania
No reports.
Luxembourg
2010 One seizure of 6 g of powder. No other psychoactive ingredients were detected.
Malta
No reports.
Netherlands
2009 Four collected samples of powders (amount not stated) analysed by the Drugs Informatie en Monitoring Systeem (DIMS) project.
2010 Four seizures of powder (amount not stated).
2010 1006 collected ‘speed’ samples (powders) analysed, 10 % contained 4-methylamphetamine (DIMS).
2011 946 collected ‘speed’ samples (powders) analysed, 9 % contained 4-methylamphetamine (DIMS).
2011 Out of 1,560 amphetamine seizures (powders) analysed: 81 samples containing amphetamine in combination with 
4-methylamphetamine and 27 samples contained 4-methylamphetamine only. 37 samples contained a little amount of 
4-methylamphetamine. This includes 24 seizures of powder that weighed 6.3 kg.
2012 Up to May, of 461 amphetamine seizures (powders) analysed, 30 samples contained amphetamine in combination with a substantial 
amount of 4-methylamphetamine and 11 samples contained 4-methylamphetamine only. 44 amphetamine samples contained 
minimal amounts of 4-methylamphetamine.
2012 Up to June, of 685 collected ‘speed’ samples analysed (amount and type of samples not stated), 17 % contained 
4-methylamphetamine; also six tablets containing both amphetamine and 4-methylamphetamine (DIMS).
Poland
2011 Seizure of four powders each weighing 2 g (two light yellow and two light pink); contained predominantly amphetamine sulfate 
(83–86 %) with a ‘small amount’ of 4-methylamphetamine and DPIA.
Portugal
No reports.
Romania
No reports.
Slovakia
No reports.
Slovenia
No reports.
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Year/ordered 
by country
Amount and details of the seizure/collected sample
Spain
2012 Three collected samples of a powder (unknown amount) also containing amphetamine, caffeine, di-(β-phenylisopropyl)-amine, 
N-formylamphetamine, N-(-phenylisopropyl)benzaldimine.
Sweden
2009 One seizure of 7.28 g of yellow powder.
2010 4-Methylamphetamine was found in 198 cases together with already controlled substances (e.g. amphetamine).
2011 4-Methylamphetamine was found in 256 cases and 17 liquid samples together with already controlled substances (e.g. 
amphetamine).
United Kingdom
2010 One seizure of 0.19 g white powder also containing amphetamine and caffeine.
2011 92.8 g compressed damp-off white powder also containing caffeine.
2012 967.7 g damp off-white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of methyl group not 
confirmed).
2012 6.288 g damp white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of methyl group not 
confirmed).
2012 Plastic package containing 1.846 g white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of 
methyl group not confirmed). 
2012 8.67 g white powder also containing amphetamine (analysed by GC-MS and so position of methyl group not confirmed).
2012 36.72 g white powder also containing amphetamine (analysed by GC-MS and so position of methyl group not confirmed).
2012 0.847 g white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of methyl group not 
confirmed).
2012 13.09 g white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of methyl group not 
confirmed).
2012 3 g white powder also containing amphetamine and caffeine (analysed by GC-MS and so position of methyl group not confirmed).
2012 5.1 g white powder also containing amphetamine, paracetamol and caffeine (analysed by GC-MS and so position of methyl group 
not confirmed).
2012 Four seizures of powder (0.573 g, 0.321 g, 0.359 g, 98.1 g) also containing amphetamine and caffeine (4-methylamphetamine 
identified by GC-MS by comparison to a standard).
2012 1.63 g powder also containing amphetamine and caffeine (4-methylamphetamine identified by GC-MS by comparison to a 
standard).
2012 72 g compressed off-white damp substance also containing amphetamine (< 1 %).
2012 Approximately 34 kg of powder also containing amphetamine (14 %). Although the concentration of 4-methylamphetamine was not 
determined, it was known to be lower than the amphetamine present.
Croatia
2010 In 2010 there were only ten cases of seizures where 4-methylamphetamine was present. Total weight of these seized drugs was 
268.01 g.
2011 Out of 6,324 individual seizures during 2011, traces of 4-methylamphetamine were found in 18 cases, or 0.28 % of total number of 
seizures. Total weight of seized drugs which contained traces of 4-methylamphetamine was 251.07 g.
2012 19 cases (total amount 747.62 g) of 4-methylamphetamine mixed with amphetamine.
2012 In two separate cases (total amount 4.12 g), 4-methylamphetamine concentrations were 2.7 % and 2.9 %. Powders also contained 
amphetamine.
Turkey
No reports.
Norway
2009 One seizure of 120 tablets in a commercial product called ‘Green Stinger’. [A product bearing this name is sold on the internet as an 
‘ephedrine weight-loss product’ (4-methylamphetamine is not listed as an ingredient on this product).]. Analysis revealed that no 
ephedrine was present, with MS-data indicating a mix of several compounds: 4-methylamphetamine, 1-phenylethylamine, 
2-phenylethylamine, β-methyl-phenethylamine, N,N-dimethyl-phenethylamine, N-benzyl-1-phenylethylamine, caffeine and 
yohimbine.
Undated Two seizures of 0.345 g and 0.136 g of powder also containing amphetamine.
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Among 15- to 16-year-old school students, lifetime prevalence 
of amphetamines use ranged from 1 % to 7 % in the 24 
Member States, Croatia and Norway with ESPAD surveys in 
2011, although only Belgium, Bulgaria and Hungary reported 
prevalence levels of more than 4 % (60). The Spanish national 
school survey reports 1 %.
Between 2005 and 2010, last year amphetamines use has 
remained relatively low and stable among the general 
population in most European countries, with prevalence levels 
of less than 3 % in all reporting countries. During this period 
an increase was reported by only one country, Bulgaria, which 
observed an increase of one percentage point in last year 
prevalence of amphetamines use among young adults. ESPAD 
school surveys conducted in 2011 suggest, overall, little 
change in the levels of experimentation with amphetamines 
among students aged 15 to 16 (EMCDDA, 2012).
I Section D. Health risks
I D1. Acute health effects
D1.1. Animal data
The reported acute toxicity data for 4-methylamphetamine 
(and comparative data for amphetamine) expressed as 
median lethal dose (LD
50
, mg/kg) in mouse models are shown 
in Table 3.
Based on the LD
50
 data, the acute toxicity of 
4-methylamphetamine appears to be similar to amphetamine 
in the mouse model. Studies by Riva et al. (1969) indicate that 
crowding potentiates the lethality of both amphetamine and 
4-methylamphetamine (the phenomenon of ‘amphetamine 
aggregation-toxicity’ has been previously noted for these type 
of compounds).
Additional toxicity data were reported by Fellows and 
Bernheim (1950). The oral LD
50
 value of 4-methyl-
amphetamine (18) for rats was found to be 150 mg/kg.
There is no information on the pharmacology or toxicology of 
dimer synthetic impurities detected in 4-methylamphetamine 
samples (Westphal et al., 2011) (19).
(18)  The authors did not specify what kind of ‘neutral salt’ had been used.
(19)  The animal pharmacology and toxicology of a dimer impurity (DPIA) 
occurring in illicit amphetamine samples has been studied. See, for example, 
Ketema et al., 1990. 
There are currently no coordinated national or European 
general population surveys on 4-methylamphetamine use. 
Further, the European school survey project on alcohol and 
other drugs (ESPAD) and other school/college/university 
surveys have not investigated or reported on 4-methyl-
amphetamine use. One online survey conducted by DAATH 
(the online discussion forum of the Hungarian Psychedelic 
Community) and the Hungarian national focal point was 
conducted 15–25 June 2012 on the forum daath.hu 
(EMCDDA–Europol, 2012). Of the 194 individuals who 
completed the survey, 4 (2.1 %) thought that they had used 
4-methylamphetamine. However the street names provided in 
two of these cases, ‘formek’ (generally associated with 
4-methylethcathinone) and ‘piko’ (generally associated with 
methamphetamine), suggest that this may be an over-
estimate. In one survey using a similar methodology to a 
previous published study (Measham et al., 2011), 330 
individuals attending gay-friendly nightclubs in South London, 
United Kingdom in July 2012 were asked about their 
knowledge and frequency of use of 4-methylamphetamine 
and amphetamine (‘speed‘) as a comparator. This was part of 
a larger questionnaire survey on the self-reported use of a 
number of other recreational drugs and new psychoactive 
substances. Of these, 16.2 % had heard of 4-methyl-
amphetamine (97 % had heard of amphetamine), 5.8 % 
reported having ever used it (43.9 % had used amphetamine), 
4.0 % had used it in the last year (16.5 % had used 
amphetamine) (personal communication from Fiona 
Measham, David Wood, Paul Dargan). It is possible that in at 
least some cases, participants reporting the use of 
4-methylamphetamine were actually referring to 
‘methamphetamine’ (N-methylamphetamine).
Given that the available data indicate that 4-methyl-
amphetamine is usually sold as amphetamine (‘speed’) it 
should be noted that EMCDDA drug prevalence estimates 
suggest that about 13 million Europeans have tried 
amphetamines (a generic term that includes both 
amphetamine and methamphetamine — and it is important to 
note that there have been no indications that 4-methyl-
amphetamine has been sold as ‘methamphetamine’), and 
about 2 million have used the drug during the last year. Among 
young adults (aged 15 to 34), lifetime prevalence of 
amphetamines use varies considerably between countries, 
from 0.1 % to 12.9 %, with a weighted European average of 
5.5 %. Last year use of amphetamines in this age group ranges 
from 0 % to 2.5 %, with most countries reporting prevalence 
levels of 0.5 % to 2.0 %. It is estimated that about 1.5 million 
(1.2 %) young Europeans have used amphetamines during the 
last year. Levels of last year use of amphetamines are higher in 
surveys among young people linked with dance-music or 
nightlife settings, with results from 2010 studies in the Czech 
Republic, the Netherlands and the United Kingdom ranging 
from 8 % to 27 %.
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increase in systolic blood pressure of 18 mmHg and diastolic 
of 16 mmHg. A dose of 2.0 mg/kg resulted in ‘severe and 
prolonged anorexia’ and volunteers ‘complained bitterly of 
gastric distress with much salivation, expectoration and 
coughing, terminating in copious vomiting of mucus 
secretions’. There was a greater increase in blood pressure 
(systolic increase of 50 mmHg and diastolic of 34 mmHg); 
these persisted for 20–30 minutes, before falling to 
approximately 20 mmHg above baseline. The authors felt that 
it was not possible to compare the effects of 
4-methylamphetamine directly to the effects of amphetamine. 
However, they stated that a dose of 1 mg/kg 
4-methylamphetamine produced a blood pressure rise about 
equal to a dose of 0.25 mg/kg amphetamine.
Shulgin and Shulgin (1997) provide some limited data on 
experiments in humans looking at all three ring-substituted 
mono-methylamphetamine isomers (2-, 3- and 4-methyl-
amphetamine). No information is provided on the methodology 
of the experiments or the number of volunteers. They describe 
2- and 3-methylamphetamine as weak anorexics that at oral 
doses of up to 150 mg cause signs of stimulation 
(talkativeness) and loss of appetite. 4-Methylamphetamine at 
an oral dose of 75 mg was said to cause ‘clear signs of 
adrenergic stimulation’ (no details are given), and at an oral 
dose of 150 mg they note ‘signs of mild toxicity such as 
salivation, coughing and vomiting’. In a self-experiment, 
‘psychedelic activity’ was reported at 160 mg oral dose and at 
80–120 mg by intramuscular injection, with a ‘plateau at two 
hours, and baseline at four hours’ (Shulgin et al., 2011: 276).
There has been one reported clinical trial of 4-methyl-
amphetamine as an anorectic agent (Aptrol) in weight 
reduction (Gelvin & McGavack, 1952). A total of 65 individuals 
were recruited for the study, with each individual acting as 
their own control, comparing clinical and adverse effects 
during the treatment and placebo arms. In total 48 were 
The majority of forensic reports, including post-mortem 
analyses, note the co-presence of caffeine in seizures, 
collected and biological samples. It is important to note that 
adverse drug interactions, such as the enhancement of the 
acute toxicity of 4-methylamphetamine (or from amphetamine 
that was co-present in many samples), should not be 
underestimated. The toxicity-potentiating effect of caffeine 
when combined with stimulants, including amphetamine, has 
been documented (Derlet et al., 1992; Sinchai et al., 2011). In 
one study, while caffeine pre-treatment potentiated the 
anorectic activity of 4-methylamphetamine, no such effect 
was seen for amphetamine (Cox & Maickel, 1976). This 
observation suggests the existence of drug interactions for 
caffeine and 4-methylamphetamine.
D1.2. Human data
One volunteer study in the 1950s investigated the clinical 
features associated with 4-methylamphetamine use. Here the 
effects of 4-methylamphetamine and other ring-substituted 
amphetamines (such as 2- and 3-methylamphetamine) were 
compared to amphetamine (Marsh & Herring, 1950). Fourteen 
male volunteers were administered 0.5 mg/kg amphetamine. 
Of these, six had systolic blood pressure increases of a 
maximum of 22–28 mmHg. These were then selected for 
further testing performed at three or four day intervals and 
administered amphetamine in doses of 0.25, 0.5 and 0.75 mg/
kg and the ring-substituted amphetamines given in doses of 
0.5, 0.75, 1.0, 1.5 and 2.0 mg/kg. Anorectic effects, along with 
physiological effects, were recorded following administration. 
At doses of 1 mg/kg, 4-methylamphetamine was noted to 
have minimal effects on blood pressure (systolic increase of 
14 mmHg, diastolic increase of 4 mmHg) and did not change 
heart rate, and volunteers reported that they were ‘not hungry’. 
At 1.5 mg/kg, nausea and perspiration were present and the 
anorexia persisted for six to ten hours; there was an average 
TABLE 3
Acute animal toxicity data for 4-methylamphetamine (and comparative data for amphetamine) expressed as median lethal dose 
(LD
50
, mg/kg). Key: a: sulphate salt; b: hydrochloride salt
Model LD
50
 4-methylamphetamine LD
50
 amphetamine Reference
Mouse, intraperitoneal administration,  
kept in isolation
136a 101a Marsh & Herring, 1950
Mouse, intraperitoneal administration,  
kept in groups of five
12b 40b Benington et al., 1965
Mouse, intravenous administration 31.0 12.5 Haas & Forth 1956
Mouse, subcutaneous administration 76 47 Haas & Forth 1956
Mouse, oral administration 115 45 Haas & Forth 1956
Mouse, subcutaneous administration,  
kept in isolation
160b 205b Riva et al., 1969
Mouse, subcutaneous administration,  
kept in groups of ten
35b 15.5b Riva et al., 1969
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D1.2.2. Clinical acute 4-methylamphetamine toxicity
A total of 20 non-fatal cases of acute 4-methylamphetamine 
toxicity or detection of 4-methylamphetamine in drug-related 
offences have been reported from five Member States 
(Belgium, France, Hungary, Sweden and the United Kingdom). 
A further non-fatal intoxication that predates the Council 
Decision 2005/387/JHA was found in the literature (Bal et al., 
1989) and is included here.
Non-fatal cases reported by Belgium:
n  There is a report of a non-fatal intoxication in August 2011 
related to consumption of a powder sold as ‘speed’. No 
clinical details are available. Toxicological analysis revealed 
a blood concentration of 4-methylamphetamine 0.120 
mg/L, no amphetamine detected, sildenafil positive.
n  One non-fatal intoxication in August 2011. No clinical 
details were provided and no reported analysis of biological 
samples. Analysis of a powder collected as part of the 
investigation was found to contain 4-methylamphetamine 
(64 %), amphetamine (16 %) and caffeine (15 %).
n  Report of a non-fatal intoxication in September 2011 with 
detection in urine of amphetamine and 
4-methylamphetamine. No clinical details were provided in 
this report.
n  Between July and August 2012, two intoxications occurred 
where trace amounts of 4-methylamphetamine were 
found. No clinical significance could be attached to the 
findings.
Non-fatal cases reported by France:
n  June 2010, report of a 40-year-old male with depression 
with intravenous injection of 1.5 g of white paste over a 
12-hour period that was believed to be amphetamine. 24 
hours later he was admitted to hospital with nausea, 
sweating, paranoia and hallucinations, and symptoms of 
depression once the effects of the substance had 
subsided. Analysis of the paste showed amphetamine 
(10 %), 4-methylamphetamine (concentration not stated). 
The patient was also taking alcohol, cannabis, olanzapine, 
carbamazepine and methadone. No biological sample 
analysis was reported.
Non-fatal cases reported by Hungary:
n  There are reports from 2012 of urine positive for 
4-methylamphetamine and amphetamine in samples 
provided to the police from two individuals who were 
tested due to drug related offences. 4-Methylamphetamine 
concentrations, the circumstances of the testing or clinical 
features present were not reported.
administered 4-methylamphetamine and then placebo, 14 
only 4-methylamphetamine and 11 only placebo. In addition, 
individuals were placed on a strict 1,000 calories per day diet. 
Treatment was initiated at 25 mg three times a day, and 
increased if tolerated to 50 mg three times a day. Weight loss 
during 4-amphetamine phase was 0.8 pounds per week 
compared to 0.2 pounds per week with placebo. The authors 
reported that there was no significant difference between 
4-methylamphetamine and placebo in terms of effects on 
blood pressure, heart rate and the ‘majority of unwanted 
effects’. There was no difference in the frequency of unwanted 
effects such as ‘weakness’, ‘giddiness’, ‘faintness’, nausea and 
vomiting associated with 4-methylamphetamine 
administration compared to placebo. There were no changes 
in haemoglobin, total leucocyte count or polymorphonuclear 
lymphocyte count with 4-methylamphetamine administration 
compared to placebo. Unwanted effects that appeared only to 
be reported during 4-methylamphetamine use were 
headache, pruritis and palpitations (all of these occurred in 
3 % of 4-methylamphetamine treated individuals).
D1.2.1. User reports
There are limited user reports discussing 4-methyl-
amphetamine. It is likely that this is because 4-methyl-
amphetamine is generally sold as amphetamine (’speed’) and 
therefore users are unaware that they are taking 
4-methylamphetamine. The reports that are available need to 
be interpreted with caution, as there was no analytical 
confirmation of the substances used.
Drugs Forum:
There is one user report describing use of 10–50 mg of a product 
that may have contained 4-methylamphetamine or 
4-methylmethamphetamine (Drugs Forum, 2008). The individual 
reported ‘headache, “din” [sic; possibly “pounding”] heart, 
nausea, nervousness and stimulation resembling ephedra’.
Bluelight:
This forum contains reports by users in France (Bluelight, 
2008). It is noted that the majority of effects experienced by 
users are negative, with positive effects rarely reported. 
Variable effects include anxiety, immediately followed by a 
feeling of empathy and euphoria, with post-use effects such as 
insomnia, cognitive disorder and mood disorder. ‘Ephedra-type’ 
stimulant effects that are described by some users as ‘terrible’ 
with both physical and psychological effects: heavy sweating, 
nausea, abdominal pains, high blood pressure, flutter, 
headache, paranoia, hallucinations, anxiety and depression. No 
information is provided about other co-used substances, 
including medicines, that could explain these effects.
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4-methylmethamphetamine; there was no analysis of 
biological samples from the patient to confirm use and 
exclude concomitant use of other substances. It is not 
possible to determine whether the effects reported were 
due to 4-methylamphetamine, alcohol or 
4-methylmethamphetamine.
D1.2.3. 4-Methylamphetamine related deaths
The first death where 4-methylamphetamine was detected 
was from the United Kingdom in October 2010. There is 
limited clinical information in this case apart from that the 
deceased was sent home from work with ‘flu-like symptoms’ 
prior to death. Post-mortem toxicological screening was also 
positive for amphetamine and cannabis. To date, there have 
been a total of 21 deaths from four Member States: Belgium 
(6 deaths), Denmark (1), the Netherlands (6), and the United 
Kingdom (8) where 4-methylamphetamine alone or in 
combination with one or more other substance has been 
detected in post-mortem samples. Based on the information 
available it is not possible to determine the significance of the 
detection of 4-methylamphetamine in relation to the actual 
cause of death. There have been no reports of 4-methyl-
amphetamine related deaths from other Member States, 
Croatia, Turkey and Norway. It should be noted that this may 
reflect that appropriate biological analysis has not been 
requested by the relevant authorities to determine whether 
4-methylamphetamine is related to a death.
Reports from Member States concerning potential 4-methyl-
amphetamine related fatalities are summarised below.
Belgium:
n  A deceased individual (unspecified age and sex) was found 
in August 2011 with powder containing amphetamine, 
caffeine and 4-methylamphetamine. Blood concentration 
(not specified whether this was ante- or post-mortem) of 
4-methylamphetamine 1.98 mg/L, amphetamine 
1.70 mg/L, tetrahydrocannabinol (THC) 0.0024 mg/L and 
MDMA 0.23 mg/L. No further details were provided.
n  A deceased individual (unspecified age and sex) used 
‘speed’ in August 2011. Blood concentration (not specified 
whether this was ante- or post-mortem) of 4-methyl-
amphetamine 1.2 mg/L, amphetamine 0.715 mg/L. No 
further details were provided.
n  A deceased individual (unspecified age and sex) found in 
September 2011 with powder containing amphetamine, 
caffeine and 4-methylamphetamine. Blood concentration 
(not specified whether this was ante- or post-mortem) of 
4-methylamphetamine 1.45 mg/L, amphetamine 
0.75 mg/L and positive for olanzapine. No further details 
were provided.
Non-fatal cases reported by Sweden:
n  Between April 2011 and March 2012 the National Board of 
Forensic Medicine analysed six urine samples that tested 
positive for 4-methylamphetamine; in all cases 
amphetamine was also detected. 4-Methylamphetamine 
concentrations, the circumstances of the testing or clinical 
features present were not reported.
n  May 2012: four positive urine samples for 4-methyl-
amphetamine reported from two different hospitals 
(Mälarsjukhuset and Västmanlandssjukhus hospital 
emergency wards) as part of the joint STRIDA project  (20). 
4-Methylamphetamine concentrations, the circumstances 
of the testing or clinical features present were not reported.
Non-fatal cases reported by the United Kingdom:
n  April 2012: 20-year-old male (present with a 16-year-old 
female who died, see below) who was suspected to have 
used 4-methylamphetamine. Trace amount of 
amphetamine in the antemortem blood and medicines 
(administered at hospital) were detected. 
4-Methylamphetamine detected in blood: 0.13 mg/L 
obtained some hours after consuming the drug. Also, 
mephedrone found in urine only. A further individual as 
part of this case (23-year-old male) also had a blood 
sample taken that detected trace amphetamine and 
4-methylamphetamine (0.23 mg/L). Analysis of an off-
white damp substance seized as part of the investigation 
detected 4-methylamphetamine and (<1 %) amphetamine.
Non-fatal cases reported in the literature:
n  There is a single published case report of a 40-year-old 
male who reported snorting (nasal insufflation) 
‘amphetamine after consumption of five pints of lager and 
an unknown amount of sherry and barley wine’ (Bal et al., 
1989). Within a ‘few minutes’ started to feel unwell with a 
‘bad feeling in head, unable to focus eyes, dry mouth, 
palpitations’ and his vision became bright and shimmery. 
On arrival in the emergency department, approximately one 
hour after use, he was noted to have sympathomimetic 
clinical features (tachycardia with heart rate of 150 beats 
per minute, hypertension with a blood pressure of 
200/120 mmHg, dilated pupils and nystagmus). He was 
treated with the beta-blocker practolol; this reduced his 
heart rate to 115 but predictably worsened his hypertension 
to 240/160 mmHg. He was discharged from hospital within 
48 hours, but appeared to have difficulty in sleeping and 
persistent feelings of extreme anxiety without obvious 
cause for several weeks after use. Analysis of powder by 
GC-MS detected 4-methylamphetamine and 
(20) See Bäckberg et al., (2011) for further details of the STRIDA project. 
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2011 and one in 2012). In a further death, no 
concentrations were reported. No clinical details or 
circumstances of these deaths are available.
–  2011 Case 1: 4-methylamphetamine 1.4 mg/L, 
amphetamine 0.3 mg/L.
–  2011 Case 2: 4-methylamphetamine 0.98 mg/L, 
amphetamine 1.7 mg/L.
–  2011 Case 3: 4-methylamphetamine 2.3 mg/L, 
amphetamine 0.35 mg/L.
–  2011 Case 4: 4-methylamphetamine 2.2 mg/L, 
amphetamine 0.04 mg/L, MDMA <0.01 mg/L.
–  2012 Case 1: 4-methylamphetamine 0.5 mg/L, 
amphetamine 0.6 mg/L.
–  2012 Case 2: 4-methylamphetamine and amphetamine 
detected (concentrations not reported for either).
The United Kingdom:
Eight deaths with analytical confirmation:
n  October 2010: A 33-year-old male was sent home from 
work with flu-like symptoms. No further details are 
available. Post-mortem blood 4-methylamphetamine 
concentration 3.49 mg/L, amphetamine 16.5 mg/L and 
cannabis detected. No other drugs or alcohol detected. 
White powder submitted for analysis, found to contain 
4-methylamphetamine and amphetamine.
n  May 2011: A 22-year-old male had taken ‘ecstasy’ the night 
before and insufflated cocaine and ‘M-CAT’. The patient 
was reported to be agitated, hot and shaking. Post-mortem 
blood 4-methylamphetamine concentration 3.77 mg/L, 
unidentified cathinones and ethanol 270 mg/L. No other 
drugs detected.
n  January 2012: A 23-year-old female was found dead. There 
were indications that she had used ketamine and 
amphetamine but neither was detected at post-mortem. 
Post-mortem blood 4-methylamphetamine concentration 
5.8 mg/L and ethanol 190 mg/L.
n  April 2012: A 16-year-old female died in hospital following 
consumption of a yellow paste in a rizzla and swallowed 
(bombing). Ante- and post-mortem samples taken. Trace 
amount of amphetamine detected in the post-mortem 
blood, insufficient volume for ante-mortem measurement. 
4-Methylamphetamine detected in blood (1.6 mg/L 
ante-mortem; 2.6 mg/L post-mortem). Possible 
explanations for the differences between ante- and 
post-mortem levels of the drug include: redistribution 
post-mortem and/or could still be ingesting the drugs due 
to ‹bolus›-type delivery from bombing. Analysis of an 
off-white damp substance seized as part of the 
investigation detected 4-methylamphetamine and 
amphetamine (<1 %). This case also involved two non-fatal 
intoxications, the details of which are presented above.
n  A 36-year-old male had a cardiorespiratory arrest in 
February 2012; no further clinical details were provided. 
Powder found on the individual contained amphetamine, 
4-methylamphetamine and caffeine. Post-mortem tissue 
(not specified what tissue) was positive for amphetamine, 
4-methylamphetamine and caffeine.
n  A 34-year-old female in March 2012 was reported to have 
consumed ketamine, cocaine and amphetamines. She 
presented with ‘extreme hyperthermia’ and died after 
cardiac arrest; no further clinical details were provided. 
Powder found on the patient contained amphetamine and 
4-methylamphetamine. Post-mortem tissue (not specified 
what tissue) was positive for amphetamine, 
4-methylamphetamine, cocaine, benzoylecognine and 
levamisole. Pre-mortem femoral blood contained 
4-methylamphetamine (0.62 mg/L), amphetamine 
(0.480 mg/L).
n  A sixth death involving 4-methylamphetamine was 
reported in July 2012 concerning a 32-year-old male. 
4-Methylamphetamine and amphetamine were detected in 
urine urine and ‘high concentrations’ of amphetamine were 
detected in blood. It is yet to be confirmed whether 
4-methylamphetamine played a role in death and no 
further clinical details are available for this case.
In two of the four cases in which a powder sample that was 
recovered as part of the investigation was analysed and found 
to contain 4-methylamphetamine, amphetamine and caffeine, 
the active substances were quantified and 4-methyl-
amphetamine was present in greater amounts than 
amphetamine (EMCDDA–Europol, 2012).
Denmark:
n  A 27-year-old man was found dead in December 2010. 
Methylamphetamine was detected; it is not stated in which 
biological sample(s) or at what concentration. Nor was not 
possible to differentiate between 2-, 3- or 4-methyl-
amphetamine. Additionally, amphetamine, morphine, 
methadone, THC and meta-chlorophenylpiperazine 
(mCPP) were detected; the concentrations of these were 
not stated, however these were reported to be ‘found in 
doses which are seen in people abusing these substances’. 
Ephedrine was also found ‘in an amount normally seen in 
people treated with this substance’. The forensic 
conclusion from the autopsy ‘suggests that 
methylamphetamine was the cause of death as the 
estimated concentration is on a level that would be lethal if 
the substance in question was amphetamine’.
The Netherlands:
n  Five deaths are reported in which post-mortem blood 
4-methylamphetamine concentrations are available (four in 
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I D3. Factors affecting public health risks
D3.1. Availability and quality of the new psychoactive 
substance on the market (purity, adulterants, etc.)
As summarised in Section C, 4-methylamphetamine is most 
commonly found in mixtures together with amphetamine and 
caffeine. 4-Methylamphetamine has been the only active 
substance in seized samples in only a few instances. This has 
been the case in some of the samples seized in Belgium, 
Denmark, France, Germany, Ireland, the Netherlands, Sweden 
and Croatia. In most cases, seized samples have not been 
quantitatively analysed and so the amount of 4-methyl-
amphetamine detected has not been reported. As a result it is 
not possible to state the relative proportion of active 
ingredients in the seized products. In cases where the amount 
of 4-methylamphetamine has been determined, this has 
varied from trace or minor components to a small number of 
reports in which 4-methylamphetamine is reported as a larger 
or main component of the mixture. Additionally, apart from 
synthetic by-products, other substances that have been 
reported in 4-methylamphetamine seizures and collected 
samples include: lactose, paracetamol, ephedrine, cannabinol, 
tetrahydrocannabinol (THC), ketamine and 4-methy l-
ethcathinone (4-MEC).
Information on price is available from Austria, Belgium and the 
Netherlands (EMCDDA–Europol, 2012). In all of these cases 
the 4-methylamphetamine was sold as ‘speed’ 
(amphetamine). In Austria, four collected samples that 
contained 4-methylamphetamine (amphetamine was the main 
active substance present) cost between EUR 15 and EUR 30/
gram. Belgium and the Netherlands reported that the prices 
were the same as for ‘speed’ (amphetamine) (EUR 10/gram).
A search of the anonymous online marketplace Silk Road (21) 
(June 2012), which specialises in the sale of products that 
would be unlawful in many jurisdictions without authority 
(particularly the sale of controlled drugs), did not find any 
4-methylamphetamine being sold by sellers purporting to be 
from the United Kingdom (EMCDDA–Europol, 2012). None of 
the countries that reported seizures found to contain 
4-methylamphetamine reported that these were linked to 
Internet sales (EMCDDA–Europol, 2012).
Germany, Italy and Sweden have reported that 4-methy l-
amphetamine is being sold as a ‘research chemical’ on the 
Internet and France reported that 4-methylamphetamine 
availability on the Internet is low (EMCDDA–Europol, 2012). 
Italy also noted that 4-methyl amphetamine was being offered 
for sale in classified adverts on the Internet in October 2011.
(21) See Barratt (2012) and Christin (2012) for further information on ‘Silk Road’. 
n  May 2012: A 40-year-old male was found dead on the 
settee at home, having previously been noticed to have 
laboured breathing. He had been complaining of breathing 
trouble during the preceding few weeks. He had had a 
kidney transplant (not known when). Had begun to use 
recreational drugs (cannabis). Cannabinoids detected in 
blood. Amphetamine (1.1 mg/L) and 
4-methylamphetamine (0.07 mg/L, low) were measured in 
femoral blood. Also detected were medicines: paroxetine, 
diazepam, metoclopramide, pseudo/ephedrine and 
quetiapine. Cause of death unclear.
n  June 2012: A 29-year-old male was found dead on the 
ground near to a pumping station. Had sent a text to his 
partner inferring suicidal intent. 4-Methylamphetamine 
was found in urine only and not blood. Amphetamine 
(observed low/recreational level) was found in blood and 
urine. Caffeine detected in blood and urine at toxic 
(overdose) levels = 184 mg/L. No other drugs detected, 
alcohol urine only (340 mg/L).
n  July 2012: A 43-year-old male was found in his work van in 
pain. Cardio-pulmonary resuscitation was started by a 
nurse who was a bystander. He was taken to hospital but 
was pronounced dead at the emergency department. He 
may have been an amphetamine user. Amphetamine 
detected in urine and blood (trace amount). 
4-Methylamphetamine detected in urine only not blood. 
Cannabinoids detected in urine. No other drugs detected.
n  July 2012: A 38-year-old male was found collapsed at his 
home address. Had a medical history of migraine, low 
mood and depression. 4-Methylamphetamine detected in 
blood (1.5 mg/L) and urine. Amphetamine detected in 
blood (trace amount) and urine. Paracetamol detected in 
blood and urine. No other drugs detected.
I D2. Chronic health effects
D2.1. Animal data
In 30-day sub-acute and three-month chronic toxicity studies 
with 4-methylamphetamine administered orally to rats and dogs 
at up to 30 mg/kg daily doses, no evidence of changes were 
observed by histological examination of various tissues, including 
heart, kidney, liver, brain, and spleen (Fellows et al., 1950).
D2.2. Human data
There are no published studies investigating the chronic 
health effects of 4-methylamphetamine in humans to date. 
However, there is the potential for long-term physical harm as 
a direct result of acute 4-methylamphetamine toxicity (e.g. 
prolonged seizures resulting in cerebral hypoxia).
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D3.2. Availability of the information, degree of 
knowledge and perceptions amongst users concerning 
the psychoactive substance and its effects
There is very limited information on commonly used Internet 
drug user discussion forums regarding the effects and 
potential health/adverse effects related to the use of 
4-methylamphetamine. As previously noted, it appears that 
exposure to 4-methylamphetamine is generally inadvertent, 
occurring when individuals are attempting to source 
amphetamine (’speed’). Therefore, it is likely that the 
information, degree of knowledge and perceptions amongst 
users concerning 4-methylamphetamine and its effects are 
likely to be negligible.
D3.3. Characteristics and behaviour of users (including 
risk factors, vulnerability, etc.)
Since the majority of exposure/use of 4-methylamphetamine 
is likely to relate to where an individual attempts to source 
‘amphetamine’ (’speed’) and there are no surveys of 
4-methylamphetamine users, there is no specific information 
as to the characteristics and behaviour of users of 
4-methylamphetamine. However, it is likely that, given 
exposure is related to the attempted sourcing of 
‘amphetamine’ (’speed’), the characteristics and behaviours of 
users should be considered to be comparable to those who 
use amphetamine.
D3.4. Nature and extent of health consequence (e.g. 
acute emergencies, road traffic accidents)
The very limited information on the acute health effects of 
4-methylamphetamine were discussed in Section D1.2.
There is insufficient information in the reported fatalities 
where 4-methylamphetamine has been detected to discuss in 
detail the circumstances of these deaths. However, from the 
information available, it does not appear that any of these 
were related to road traffic accidents. One study notes the 
detection of 4-methylamphetamine in five serum samples of 
drivers in Germany (Westphal et al., 2011; Peters et al., 2011). 
However, further information on these cases is not available to 
allow additional comment.
D3.5. Long-term consequences of use
As discussed in Sections D2.1. and D2.2., there are no animal 
or human data on the chronic health effects of 
4-methylamphetamine use. In particular, there have been no 
long-term follow-up studies to determine whether 
Slovakia undertook a structured Internet search on 5 and 21 
June 2012 in Slovak on two search engines (google.sk and 
zoznam.sk) (EMCDDA–Europol, 2012). Search terms (in 
Slovak) were: kupit ‘4-methylamphetamine’ OR predate 
‘4-methylamphetamine’ OR obchod ‘4-methylamphetamine’ 
OR trafficking with ‘4-methylamphetamine’ … ‘4-MA’ or ‘p-MA’. 
No websites selling or advertising 4-methylamphetamine were 
identified in this study.
The United Kingdom has reported that the FRANK drug 
information website (talktofrank.com) noted that 
4-methylamphetamine has also been sold using the names ‘ket 
phet’ or ‘phet ket’; however, an Internet search of these terms has 
yielded no drug-specific information (EMCDDA–Europol, 2012).
A structured search based on the EMCDDA snapshot 
methodology (EMCDDA, 2011) of the Internet sites 
balticnordic.com, tradekey.com and google.com using English 
search terms (’4-methylamphetamine’, ‘4-ma’, ‘p-tap’, ‘pal-313’, 
‘buy 4-methylamphetamine’, ‘buy 4-ma’, ‘buy p-tap’, ‘buy 
pal-313’) was conducted by the EMCDDA on 18 July 2012. No 
sites were identified that sold 4-methylamphetamine aimed at 
users (i.e. as a ‘legal high’ or ‘research chemical’). Websites 
were identified that sold 4-methylamphetamine as an 
analytical reference standard or for scientific research 
purposes. Some websites/web portals listed chemical 
suppliers that could purportedly offer 4-methylamphetamine 
for sale. No countries reported seizures or collected samples 
linked to sale of the drug on the Internet. Norway reported a 
single seizure by customs where 4-methylamphetamine was 
detected in a ‘weight loss’ product and they noted that this 
product is offered for sale on the Internet.
Where available, information from the fatal and non-fatal 
intoxication cases where 4-methylamphetamine has been 
detected suggests that the individual had attempted to source 
amphetamine (’speed’) rather than specifically 
4-methylamphetamine itself. Austria, Belgium, and the 
Netherlands have reported that 4-methylamphetamine has 
been sold at street level as ‘speed’ (amphetamine) and that 
there does not appear to be a specific demand for 
4-methylamphetamine (EMCDDA–Europol, 2012).
Overall, based on this information, it is likely that most 
individuals are exposed to 4-methylamphetamine 
inadvertently after consuming an illicit amphetamine product 
that contains 4-methylamphetamine or a mixture of 
4-methylamphetamine and other active substances (most 
commonly amphetamine and/or caffeine).
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estimate whether 4-methylamphetamine is associated with 
greater healthcare costs than other stimulant drugs.
I  E5. Possible effects related to the cultural context, for example marginalisation
There is no information to be able to determine the impact of 
4-methylamphetamine in this area.
I  E6. Possible appeal of the new psychoactive substance to specific population groups within the general population
At this time, there does not appear to be any specific demand 
for 4-methylamphetamine within the general population nor 
within sub-populations who are usually associated with higher 
use of recreational drugs and new psychoactive substances.
I Section F. Involvement of organised crime
I  F1. Evidence that criminal groups are systematically involved in production, trafficking and distribution for financial gain
The available information suggests that 4-methylamphetamine 
is produced and trafficked by the same organised crime 
groups that are involved with the production and trafficking of 
amphetamine. However, there is no specific information that 
criminal groups are systematically involved in the production, 
trafficking and/or distribution of 4-methylamphetamine for 
financial gain (EMCDDA–Europol, 2012).
The only Member State to have reported the detection of illicit 
production of 4-methylamphetamine is the Netherlands. In 
2010, 4-methylamphetamine was detected in three illicit 
amphetamine production laboratories. In August 2011, traces 
of 4-methylamphetamine were found at an amphetamine 
crystallisation site. It is not clear in these cases whether those 
involved in the production were aware that they were 
producing 4-methylamphetamine. However, information from 
Dutch police notes that some producers believed that they 
were attempting to produce amphetamine using the precursor 
BMK, but they were actually using 4-methyl-BMK, and, as a 
result, were inadvertently producing 4-methylamphetamine. 
No other countries reported illicit production of 
4-methylamphetamine.
There have been five reports where 4-methylamphetamine that 
originated in the Netherlands was detected in seizures crossing 
4-methylamphetamine users are at greater risk of health 
deterioration later in life, or of developing chronic or life-
threatening medical conditions.
D3.6. Conditions under which the new psychoactive 
substance is obtained and used, including context-
related effects and risks
As previously noted, it appears that the sourcing and use of 
4-methylamphetamine generally related to individuals 
attempting to source amphetamine (’speed’). It is likely that 
4-methylamphetamine is used in the same environments as 
amphetamine. This would be typically (but not restricted to) 
home environments, bars/pubs, discotheques/nightclubs and 
outdoor music festivals.
I Section E. Social risks
I E1. Individual social risks
There is no information available to determine the impact of 
4-methylamphetamine in this area.
I E2. Possible effects on direct social environment
There is no information available to determine the impact of 
4-methylamphetamine in this area.
I E3. Possible effects on society as a whole
There are five reports of ‘minor crime’ (concerning males aged 23, 
39 and 40 and females aged 26 and 46) and one case of ‘severe 
crime’ (22-year-old male) from Sweden between April 2011 and 
March 2012. In addition to 4-methylamphetamine, other drugs 
were also reported (amphetamine in all cases, ‘thc-acid’ in two 
cases and benzodiazepine, buprenorphine and alcohol in one 
case). Information was not available to allow further comment. 
One study notes the detection of 4-methylamphetamine in five 
serum samples of drivers in Germany (Westphal et al., 2011; 
Peters et al., 2011). However, further information on these cases 
are not available to allow further comment.
I E4. Economic costs
Given the lack of information available on acute health 
emergencies and healthcare utilisation related to the use of 
4-methylamphetamine, it is not possible at this time to 
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international borders to Germany, France and the United 
Kingdom. These seizures can be summarised as follows:
2011:
n  9 kg a yellow liquid containing 4-methylamphetamine and 
amphetamine seized in France whilst in transit from the 
Netherlands to the United Kingdom.
n  81.7 kg of a white paste containing 4-methylamphetamine, 
caffeine (19 %) and amphetamine seized in France whilst 
in transit from the Netherlands to Spain.
n  10 kg of a white powder found in a rental car entering 
Germany from the Netherlands. The powder was found to 
contain amphetamine, 4-methylamphetamine, caffeine and 
traces of 4-methyl-BMK. Intelligence in this case suggested 
that the arrested person had smuggled a few shipments of 
amphetamine to Germany and Spain in the preceding 
months.
2012:
n  2.22 kg of a powder containing amphetamine and 
4-methoxyamphetamine was seized during a police check 
on an individual travelling from the Netherlands to 
Germany.
n  147 kg of paste containing 4-methylamphetamine, caffeine 
and amphetamine was seized in Lille, France whilst in transit 
to the United Kingdom. This is the largest seizure of 
4-methylamphetamine reported to the EMCDDA and 
Europol.
I  F2. Impact on the production, trafficking and distribution of other substances, including existing psychoactive substances as well as new psychoactive substances
The majority of seizures and detections have been of 
4-methylamphetamine with amphetamine, often also with 
caffeine (as discussed above). There is nothing to suggest that 
distribution networks other than those established for 
amphetamine are being used. Based on the information 
available to ECMDDA and Europol, it does not appear that the 
production, trafficking and distribution of 4-methyl-
amphetamine impacts on other existing psychoactive 
substances or new psychoactive substances, except 
amphetamine.
I  F3. Evidence of the same groups of people being involved in different types of crime
As discussed in above, the available information suggests 
that 4-methylamphetamine is produced and trafficked by the 
same organised crime groups that are involved with the 
production and trafficking of amphetamine (EMCDDA–
Europol, 2012).
I  F4. Impact of violence from criminal groups on society as a whole or on social groups or local communities (public order and safety)
No information has been received by Europol on incidents of 
violence from criminal groups in connection specifically with 
4-methylamphetamine.
I  F5. Evidence of money laundering practices, or impact of organised crime on other socioeconomic factors in society
No information has been received by Europol on incidents of 
money-laundering specifically in connection with 
4-methylamphetamine.
I  F6. Economic costs and consequences (evasion of taxes or duties, costs to the judicial system)
There is no information available to determine the impact of 
4-methylamphetamine in this area.
I F7. Use of violence between or within criminal groups
There is no information available to determine the impact of 
4-methylamphetamine in this area.
I  F8. Evidence of strategies to prevent prosecution, for example through corruption or intimidation
There is no information available to determine the impact of 
4-methylamphetamine in this area.
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I Introduction
The effect of a drug results from the interaction between the 
drug and one or more protein targets, which then triggers a 
biochemical response and, eventually, the desired effect for 
the drug user. Hence, by knowing which protein targets a drug 
may bind to, we can predict and rationalise the effects that a 
drug may cause to a person. In this analysis of 4-methyl 
amphetamine, we utilised our in silico target prediction 
algorithm which is able to anticipate drug targets given a 
chemical structure. The predicted targets can then be used to 
elucidate possible effects or mechanism-of-action, in addition 
to possible side effects of 4-methylamphetamine.
I How psychoactive drugs affect the brain
When applied in a recreational setting, drug users generally 
seeks the ‘high’ effect which produces the feeling of pleasure 
when consuming psychoactive drugs (1). The reward circuit, 
which consists of brain structures that regulate and control this 
pleasurable effect, is located in the limbic part of the brain (1) 
and it is stimulated by neurotransmitters, in particular dopamine 
and serotonin, but also others such as noradrenaline (2). 
Psychoactive substances such as MDMA 
(methylenedioxymethylamphetamine, commonly known as 
‘ecstasy’) and cocaine increase the level of the above 
neurotransmitters, hence over-stimulating the reward circuit in a 
variety of ways (2). MDMA does this by blocking the clearance or 
re-uptake of serotonin from the synapses of the nerve cells while 
cocaine blocks the re-uptake of dopamine, in addition to 
serotonin and noradrenaline (2).
I Analysis of 4-methylamphetamine
FIGURE A1
The chemical structure of 4-methylamphetamine
NH2
We subjected the compound to be assessed, 4-methyl-
amphetamine, to a target prediction algorithm to anticipate its 
effects in man. For this purpose, the top 20 protein targets 
anticipated for 4-methylamphetamine were analysed as 
follows:
 1. Serotonin transporter
 2. Monoamine oxidase A
 3. Indoleamine 2,3-dioxygenase
 4. Tyrosine-protein kinase CSK
 5. Monoamine oxidase B
 6. Carbonic anhydrase II
 7. Carbonic anhydrase I
 8. Carbonic anhydrase XII
 9. Carbonic anhydrase III
10. Carbonic anhydrase VA
11. Estrogen receptor beta
12. Estrogen receptor alpha
13. Nitric oxide synthase, inducible
14. Nitric-oxide synthase, endothelial
15. Nitric-oxide synthase, brain
16. Aminopeptidase N
17. Carbonic anhydrase VB
18. Carbonic anhydrase IX
19. Carbonic anhydrase IV
20. Arachidonate 15-lipoxygenase
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A, with no activity noted on MAO B and is 20 times more 
potent at inhibiting MAO A than amphetamine 
(K
i
 = 0.22µM in vitro) (8).
It is worth noting here that dopamine transporter (DAT), which 
has been found to interact with amphetamine (9), was not 
predicted here. The interaction between DAT and 
amphetamine blocks the clearance or re-uptake of dopamine, 
causing the increase of dopamine level in the brain (10). As 
amphetamine and 4-methylamphetamine are structurally 
similar, there is a possibility that 4-methylamphetamine may 
also interact with DAT. This implies that while the in silico 
target prediction was able to generate targets relevant to 
4-methylamphetamine, i.e. SERT and MAO, our model may not 
fully cover the biological space relevant to the chemical 
structure of 4-methylamphetamine. This limitation will be 
discussed further at the end of this section.
I Possible toxicities of 4-methylamphetamine
Serotonin syndrome
Some possible toxicities of 4-methylamphetamine due to the 
elevated level of serotonin in the brain are listed in Table A1. 
These effects resembles the serotonin syndrome often seen in 
PMA (5) and amphetamine users (11) and may be seen within 
an hour of administration.
I  Possible mechanism-of-action of 4-methylamphetamine
From the list of the top 20 targets predicted for 4-methyl-
amphetamine, it is hypothesised that 4-methylamphetamine 
increases the level of neurotransmitters in the reward circuit 
via the following mechanisms:
n  The inhibition of serotonin transporter (SERT), which is 
responsible for the re-uptake of serotonin. Blocking SERT 
increases the level of serotonin in the nerve terminals, 
consequently over-stimulating the reward circuit (3). 
MDMA and paramethoxyamphetamine (PMA), which, like 
4-methylamphetamine, are analogues of amphetamine, 
also block serotonin reuptake (2, 4, 5). PMA is abbreviated 
by some authors as 4-MA, therefore that abbreviation is 
not used in this report for 4-methyl amphetamine due to the 
potential for confusion of the two.
n  The inhibition of both monoamine oxidase (MAO) A and B. 
These enzymes are responsible for the conversion of 
monoamine-based neurotransmitters into their inactive 
forms, which are not able to stimulate the reward circuit 
any further (6). MAO A is responsible for the metabolism 
of serotonin, dopamine and noradrenaline while MAO B 
solely metabolises dopamine, and, given the anticipated 
activity on both targets, effects on all neurotransmitters 
listed are to be expected (6). The inhibition of MAO and the 
consequential effects have also been observed when 
amphetamine is consumed (5, 7). PMA solely blocks MAO 
TABLE A1
The acute toxicities anticipated for 4-methylamphetamine based on the targets predicted, such as euphoria, hyperthermia and 
anorexia. These effects resemble the serotonin syndrome often seen in amphetamine, methamphetamine and PMA users (5,11).
Acute toxicity Notes
Euphoria Increased dopamine and serotonin levels stimulate the reward circuit in the limbic system, 
hence producing the feeling of euphoria (2).
Hyperthermia Serotonin and dopamine stimulates the thermal regulatory circuit in the hypothalamus causing 
an increase in body temperature (12, 13). PMA have been found to dramatically increase body 
temperature, thought to be due to the dramatic increase of serotonin through the concurrent 
inhibition of serotonin re-uptake and MAO A serotonin conversion (5, 8).
Anorexia A high level of serotonin in the hypothalamus has been found to reduce appetite (3, 6). In 
addition, it was found that anorexic patients show high level of serotonin in the brain (14).
Hallucinogenic Hallucinations are expected due to the stimulation of the frontal cortex and visual cortex by both 
serotonin and dopamine (4).
Decreased fatigue, increase arousal, insomnia These toxic effects are caused by the high level of noradrenaline, adrenaline and dopamine 
(collectively known as catecholamine) (3, 6).
Locomotor stimulation/hyperactivity These effects are a result of high level of dopamine (15), which is rarely seen in PMA users as 
this compound has only a weak effect on dopamine levels (16).
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constrict blood vessels and causes platelet aggregation, 
leading to blood clot (22). These effects can lead to 
complications such as arrhythmia (irregular heartbeat), 
hypertension (high blood pressure) as well as myocardial 
infarction (heart attack) where the blood supply to the heart is 
blocked, causing heart cells to die (3). Acute myocardial 
infarction has been reported in patients injecting themselves 
with amphetamine, which was seen an hour after injection 
(22, 23). In addition, the hypertensive effect of noradrenaline 
can also be extended to the blood vessels in the brain, causing 
cerebral hypertension (4). This can lead to complications such 
as cerebrovascular accident (stroke), which has been reported 
in conjunction with the use of MDMA (24) and 
amphetamine (25).
In addition to the increase in noradrenaline, the inhibition of 
endothelial nitric oxide synthase (eNOS) by 4-methyl-
amphetamine was found to also cause both hypertension and 
myocardial infarction (6). eNOS produces the compound nitric 
oxide (NO) in the blood vessel (6). NO causes the dilation of 
blood vessel and is also an anti-atherogenic where it prevents 
the build-up of plaque in the blood vessel, hence reducing the 
likelihood of myocardial infarction (26). In a study by Archer et 
al. (27), it was found that deficiency of NO was seen in 
patients diagnosed with pulmonary hypertension who had 
also stopped taking fenfluramine and dexfenfluramine for 
several years. The reason for this was not established in the 
study but from the results of the target prediction we 
reasoned that this may be due to the interaction between the 
amphetamine analogues and eNOS.
Neurotoxicity
Long-term use of MDMA causes enhanced release of 
dopamine in the brain, which can be damaging to neurons and 
in particular the serotonergic neuron in the striatum (28, 29). 
In addition, MDMA also causes 2-hydroxybenzoic acid 
(salicylic acid) to be hydrolysed to 2,3-dihydroxybenzoic acid, 
a free radical that can damage the serotonergic neurons (30). 
The damage to the serotonergic nerve damage has been 
found to have an effect on verbal memory. In a study done on 
MDMA users who had ceased from using the drug for a mean 
of three years, little improvement was seen on the verbal 
memory test (31). In addition, in a study done by Ernst et al. 
(32), methamphetamine (N-methylamphetamine), which is 
neurotoxic to both dopaminergic and serotonergic neurons, 
showed that this is a long-term effect even in 
N-methamphetamine users who had since abstained.
I Other possible effects of 4-methylamphetamine
Although the literature support for the possibility of 
amphetamine and its analogue to be carcinogenic is still 
From Table A1, it can be seen that by knowing the targets 
modulated by a drug, in this case 4-methylamphetamine, we 
can then establish possible side effects in addition to 
mechanism-of-action. Using anorexia as a symptom to 
illustrate this, 4-methylamphetamine is likely to increase the 
level of serotonin available in the synapses. High levels of 
serotonin in the hypothalamus have been found to reduce 
appetite (3, 6) and it was found that anorexic patients showed 
high level of serotonin in the brain (14). Additionally, as 
amphetamine was once marketed as a diet pill as it 
suppresses the appetite (17), we rationalise that anorexia may 
be a potential toxicity for 4-methylamphetamine as well. 
Interestingly, fenfluramine, another amphetamine analogue, 
was also once marketed as a diet pill and a safer alternative to 
amphetamine, which was taken off the market due to abuse 
potential (17). In addition, fenfluramine was found to cause 
devastating long-term side effects to the heart, lungs and 
nerves (17–19).
‘Amphetamine psychosis’
When amphetamine is repeatedly taken over several days, 
symptoms resembling an acute schizophrenic attack, i.e. 
paranoia, hallucinations and aggressive behaviour where drug 
users are detached from reality, can occur (3), an effect known 
as ‘amphetamine psychosis’ (3). Psychosis is also seen in 
long-term methamphetamine users (4). From the targets 
predicted for 4-methylamphetamine, in particular 
indoleamine-2,3-deoxygenase (IDO), amphetamine psychosis 
may be a possible toxicity of 4-methylamphetamine given that 
IDO is a target for the treatment of schizophrenia (20). It has 
been found that in schizophrenic patients the level of IDO is 
reduced while tryptophan-2,3-deoxygenase (TDO) is elevated, 
and both enzymes are responsible for the metabolism of 
tryptophan. When IDO is blocked, tryptophan is predominantly 
metabolised by TDO, subsequently producing the metabolite 
kynurenine acid (KYNA) (20, 21). KYNA is an endogenous 
N-methyl-D-aspartate (NMDA) receptor antagonist which 
upon binding to the NMDA receptor causes an increase in 
dopaminergic activity and decrease in glutaminergic activity, 
leading to psychosis (20). This effect can also be seen when 
ketamine, an exogenous NMDA receptor antagonist, is taken 
(20). In addition, KYNA also blocks the α-7-nicotinic 
acethylcholine receptors, which causes cognitive 
impairment (20).
Cardiac-related complications
As postulated earlier in ‘Possible mechanism-of-action of 
4-methylamphetamine’, 4-methylamphetamine increases the 
level of neurotransmitters, i.e. serotonin, dopamine and 
noradrenaline (2). An increase in noradrenaline has been 
found to be connected to cardiac related complications (22). 
Noradrenaline increases heart contraction and heart rate, 
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I Limitations of the study
The target prediction performed here covers a relatively large 
biological space comprising 894 protein targets. Each of these 
protein targets is represented by relevant chemical spaces, 
which are defined by particular chemical structures. Given the 
computational procedure performed here, we still need to 
establish the extent to which the chemical space in the target 
prediction is representative of the chemical structures specific 
to psychoactive drugs, in order to have a high confidence in 
the predictions generated. While a general validation of the 
target prediction algorithms used here has already been 
performed, this step will be the further explored in the near 
future.
lacking, based on the prediction of aminopeptidase N, 
carbonic anhydrase, protein tyrosine kinase Csk and 
arachidonate 15-lipoxygenase, 4-methylamphetamine may 
also cause cancer (though given the acute effects, this might 
only sometimes be relevant in practical settings). 
Aminopeptidase N have been found to be over expressed in 
non-small lung, colon and prostate cancer cells (33). Carbonic 
anhydrase catalyzes the conversion of water and carbon 
dioxide into bicarbonate and the clinical significant of the 
subtypes of this enzyme is still unclear (34). However, 
carbonic anhydrase XII have been found to regulate the acidity 
of the microenvironment in cancer cells, which modulates 
tumour malignant phenotype (34). In addition, it was found 
that CA12 is over expressed in renal cancer cells (35) and 
breast cancer cells (34). Protein tyrosine kinase Csk has been 
suggested to be an antioncogene; it down regulates the 
expression of oncogenes that can lead to cancer 
transformation (36). In addition, arachidonate 15-lipoxygenase 
was found to suppress the progression of prostate 
cancer (37). Arachidonate 15-lipoxygenase has also been 
found to be highly expressed in the airways of asthmatic 
patients, suggesting possibly causing inflammation of the 
airways (38).
I  Tolerance and dependence potential of 4-methylamphetamine
After prolonged use, amphetamine and N-methamphetamine 
abusers develop tolerance and decrease susceptibility 
towards the effect of the drug (3, 5) due to the depletion of 
neurotransmitters i.e. serotonin and dopamine in the brain 
after prolonged use. Due to the tolerance developed, users 
tend to increase drug intake, hence becoming dependent to 
achieve the ‘high’ effect, which is often the case in 
amphetamine users (3). Given the similar bioactivity spectra 
expected for 4-methylamphetamine, compared to 
amphetamine, similar dependence potential is predicted.
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I Council Decision
Council Decision 2013/129/EU of 7 March 2013 on subjecting 
4-methylamphetamine to control measures
THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Council Decision 2005/387/JHA of 10 May 2005 on the information 
exchange, risk-assessment and control of new psychoactive substances (1), and in 
particular Article 8(3) thereof,
Having regard to the initiative of the European Commission,
Whereas:
(1) A Risk Assessment Report on 4-methylamphetamine was drawn up on the basis of 
Article 6 of Decision 2005/387/JHA by a special session of the extended Scientific 
Committee of the European Monitoring Centre for Drugs and Drug Addiction, and was 
subsequently received by the Commission on 29 November 2012.
(2) 4-methylamphetamine is a synthetic ring-methylated derivative of amphetamine which 
has predominantly been seized in powder and paste form in samples containing 
amphetamine and caffeine, but which has also appeared in tablet and liquid form. It has 
emerged on the illicit amphetamine market where it is sold and used as the controlled 
drug, amphetamine. There has been one report of the substance being detected in a 
commercial product sold on the internet. The main chemical precursor for the synthesis of 
4-methylamphetamine is 4-methylbenzyl methyl ketone (4-methyl-BMK), which appears to 
be commercially available on the internet and is not controlled under the 1988 United 
Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
(3) The specific physical effects of 4-methylamphetamine have been rarely reported by 
users, since users are typically unaware that they have taken the substance. However, the 
few reports that are available suggest that it has stimulant-type effects. Limited data 
available relating to humans suggest that the adverse effects of 4-methylamphetamine 
include hyperthermia, hypertension, anorexia, nausea, perspiration, gastric distress, 
coughing, vomiting, headache, palpitations, insomnia, paranoia, anxiety and depression. 
Current data is not sufficient to determine the relative dependence-producing potential of 
the substance.
(4) According to the limited data sources available, the acute toxicity of 
4-methylamphetamine is similar to that of other stimulants. Certain evidence suggests 
that a combination of 4-methylamphetamine with other substances, including 
amphetamine and caffeine, may result in a higher risk of overall enhanced toxicity.
(5) There have been a total of 21 fatalities registered in four Member States where 
4-methylamphetamine alone, or in combination with one or more substances, especially 
amphetamine, has been detected in post-mortem samples. While it is not possible to 
determine with certainty from the information available the role of 4-methylamphetamine 
in those fatalities, in some cases the substance was the predominant drug detected, with 
(1) OJ L 127, 20.5.2005, p. 32.
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levels comparable to those found in certain cases of death caused by the consumption of 
amphetamine.
(6) 4-methylamphetamine has been detected in 15 Member States, while one Member 
State has reported the manufacture of the substance on its territory. Prevalence specific 
to 4-methylamphetamine is difficult to estimate. There is no information on specific 
demand for the substance from user groups and it is not commercially marketed through 
internet shops.
(7) The information available suggests that 4-methylamphetamine is produced and 
distributed by the same organised crime groups that are involved in the manufacture and 
trafficking of amphetamine.
(8) 4-methylamphetamine has no known, established or acknowledged medical value or 
use in the Union and there is no marketing authorisation for the substance in the Union. 
Apart from its use as an analytical reference standard and in scientific research, there is no 
indication that it may be used for any other legitimate purpose.
(9) 4-methylamphetamine is not currently under assessment and has not been under 
assessment by the United Nations system. Eight Member States control the substance 
under drug control legislation by virtue of their obligations under the 1971 United Nations 
Convention on Psychotropic Substances. Two other Member States apply the generic 
definition of phenethylamine in their national legislation to the product while one Member 
State controls it under its medicines legislation.
(10) The Risk Assessment Report reveals that there is limited scientific evidence available 
on the characteristics and risks of 4-methylamphetamine and points out that further 
studies are required on the overall health and social risks associated with the substance. 
However, the evidence available provides sufficient grounds for subjecting 
4-methylamphetamine to control measures across the Union. As a result of the health risks 
it poses, as documented in its detection in several reported fatalities, especially when 
used in combination with other substances; its strong resemblance in terms of 
appearance and effects with amphetamine; the fact that users may unknowingly consume 
the substance and its limited medical value or use, 4-methylamphetamine should be 
subjected to control measures across the Union.
(11) Since 10 Member States already control 4-methylamphetamine, subjecting it to 
control measures across the Union may help avoid problems in cross-border law 
enforcement and judicial cooperation.
(12) Union-wide control measures may also help prevent 4-methylamphetamine 
developing as an alternative to amphetamine in the illicit drug markets,
HAS ADOPTED THIS DECISION:
Article 1
The new psychoactive substance, 4-methylamphetamine, is hereby subjected to control 
measures across the Union.
Article 2
By 17 March 2014, Member States shall take the necessary measures, in accordance with 
their national law, to subject 4-methylamphetamine to control measures and criminal 
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penalties, as provided for under their legislation complying with their obligations under the 
1971 United Nations Convention on Psychotropic Substances.
Article 3
This Decision shall enter into force on the day following that of its publication in the Official 
Journal of the European Union.
Done at Brussels, 7 March 2013.
For the Council 
The President 
A. SHATTER
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Abbreviations
4-MA 4-methylamphetamine
4-MEC 4-methylethcathinone
4-methyl-BMK 4-methylbenzyl methyl ketone
5-HT 5-hydroxytryptamine
5-HTP 5-hydroxytryptophan
APAAN alpha-phenylacetoacetonitrile
API active pharmaceutical ingredient
BMK benzyl methyl ketone
CA12 carbonic anhydrase XII
CAS Chemical Abstracts Service registry number
DAT dopamine transporter
Decision Council Decision 2005/387/JHA of 10 May 2005 
on the information exchange, risk assessment and 
control of new psychoactive substances
DIMS Drugs Information and Monitoring System 
(Netherlands)
DOM 2,5-dimethoxy-4-methylamphetamine
DPIA diphenylisopropylamine
EC
50
half maximal effective concentration
ED
200
the dose required to cause a 200 % increase in 
motor activity
EMA European Medicines Agency
EMCDDA European Monitoring Centre for Drugs and Drug 
Addiction
eNOS endothelial nitric oxide synthase
ENU Europol National Units
ESPAD European school survey project on alcohol and 
other drugs
EUR Euro
EWS Early-warning system (EMCDDA–Europol)
GC gas chromatography
GC-MS gas chromatography–mass spectrometry
IDO indoleamine-2,3-deoxygenase
IUPAC International Union of Pure and Applied Chemistry
Abbreviations
K
i
dissociation constant
KYNA kynurenine acid
LC liquid chromatography
LC-MS/MS liquid chromatography tandem mass 
spectrometry
LD
50
median lethal dose
LSD lysergic acid diethylamide
MAO monoamine oxidase
mCPP meta-chlorophenylpiperazine
MDMA 3,4-methylenedioxymethylamphetamine
Meth N-methylamphetamine
mmHg millimeter of mercury
MS mass spectrometry
NFP national focal point of the Reitox network
NMDA N-methyl-D-aspartate
NMR nuclear magnetic resonance spectroscopy
NO nitric oxide
PAL-303 4-fluoroamphetamine
PAL-313 4-methylamphetamine
PAL-314 3-methylamphetamine
PAL-353 3-fluoroamphetamine
PMA para-methoxyamphetamine
p-MA para-methylamphetamine or 
4-methylamphetamine
PNMT phenethanolamine N-methyltransferase
SERT serotonin transporter
TDO tryptophan-2,3-deoxygenase
THC tetrahydrocannabinol
UN United Nations
USD US dollars
WHO World Health Organization
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